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1A. Theoretical Part
Part One:
Quorum sensing system and biological activity of furanones
I Introduction
1. Primary and secondary metabolites
In the living world, metabolism is the ability to produce energy and all compounds
useful for life through complex bioprocesses from suitable nutriments. In the case of plants,
these nutriments can be extracted from the soil, or produced by photosynthesis. For animals,
the nutriments come from the food.
The first stage is the primary metabolism. It concerns the processes which occur on a
large scale, such as cell respiration, growth, and energy storage. The products are called
primary metabolites. These metabolites can be for instance polysaccharides like chitin,
cellulose, starch, as well as amino acids and proteins.
Under particular conditions, regulated by enzymes or signalling compounds, some of
these primary metabolites are involved in other bioprocesses whereby they can be
transformed into very specific molecules. This is the secondary metabolism, and the products
are the secondary metabolites. These metabolites are always produced in small amounts. They
have very specific activities and can have very different purposes. Secondary metabolites can
be pigments, flavour compounds, pheromones, hormones, antibiotics, and so on. They belong
to various families such as terpenes, which can be flavour compounds like (–)-menthol (1),
carotenoids like β-carotene (2), steroids like testosterone (3). Other well-known secondary
metabolites are alkaloids like nicotine (4), morphine (5), or taxol (6), as well as antibiotics
such as the penicillins (e.g. 7, penicillin G), pristinamycin (8), spiramycin, which is a mixture
mainly composed of the compounds 9a, 9b, and 9c.
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32. Secondary metabolites and cell-to-cell communication
2.1 Autoregulatory factors
Very specific conditions are required for the production of secondary metabolites in
bacteria. For instance, a γ-butyrolactone called A-factor (10) induces the production of the
natural antibiotic streptomycin 16 by the mutant strain Streptomyces griseus [1,2]. Moreover,
it is also essential for aerial mycelium formation, and it can activate sporulation and even the
synthesis of a yellow pigment. In fact, A-factor is involved in a regulatory cascade. It binds to
a specific protein, called A-factor binding protein, which regulates the expression of the genes
responsible for streptomycin synthesis, sporulation and so on.
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4Other natural γ-butyrolactones have similar properties. Virginiae butanolides VB-A
(11), VB-B (12), and VB-C (13) [2] extracted from Streptomyces virginiae are regulatory
factors for the synthesis of virginiamycin, which is a mixture of two main components:
virginiamycin M (14) and virginiamycin S (15). Although the structures of the three
compounds 11-13 are very close to that of the A-factor (10), they only regulate the
virginiamycin synthesis. They are not active on Streptomyces griseus, so they do not regulate
the synthesis of streptomycin 16. In the same way, A-factor (10) does not activate
virginiamycin production.
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52.2 Biofilms
Free-living bacteria cannot survive very long. They can be destroyed by antibiotics,
other bacteria, or by an immune system. In order to survive, bacteria have to form colonies.
These colonies must be protected from aggressive agents. Such colonies are called biofilms.
Nowadays, the mechanism of biofilm formation is well-known (Figure 1). In a first
stage, bacteria find a favourable environment. They fix themselves onto a surface and begin to
proliferate. When a critical concentration of bacteria, which is called quorum, is obtained,
they begin to form a matrix. This matrix is generally made from polysaccharide derivatives.
The colony grows inside the matrix, which contains channels in order to allow the circulation
of nutriments. In addition, the matrix offers the bacteria a physical protection. At a later time,
free-swimming bacteria leave the colony and try to find other places for new colonies, and so
on [3].
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6Figure 1: Different steps of the formation of a biofilm [3].
The main issue with biofilms is that it is almost impossible to remove them,
chemically and physically. In fact, the matrix has very strong adherence forces onto the
surface: even mechanical cleaning is difficult. Moreover, bacteria inside the matrix produce
enzymes in order to prevent toxic compounds to penetrate into the colony. As a consequence,
it is impossible to destroy biofilms with strong acids or bases or other corrosive chemicals.
Even antibiotics are not efficient either, since they cannot diffuse into the matrix.
2.3 How to fight biofilms of pathogens?
People who suffer from cystic fibrosis are very sensitive to bacterial infections of their
lungs. As they are treated essentially with antibiotics, they are more and more exposed to
resistant pathogens. When resistant bacteria form biofilms, the only way to cure these
patients, up to date, is lung transplantation. This extreme example shows the potential interest
of finding new techniques to decrease the virulence of pathogens.
A first possibility against biofilm formation is to prevent bacteria from adhering to a
surface. In fact, if bacteria cannot fix themselves onto a surface, they will never be able to
form a biofilm. This is particularly interesting for drinking-water pipes, air conditioning
systems and hot water networks. Recently, in France, several cases of contamination with
Legionella pneumophila were reported. Some of these contaminations occurred in French
7hospitals, where bacteria had colonized the hot water system network. Patients were
contaminated by having a shower for instance.
We explained that biofilm formation involves a change in the behaviour of bacteria:
starting from free-living bacteria, they differentiate and specialize their functions to perform
specific tasks in the colony. Which factors contribute to this behaviour changes? When
bacteria form an organized colony, how can they communicate to each other? If we could
interfere with this system, would it be possible to block biofilm formation?
3. Quorum sensing
3.1 Definition
Free-living bacteria produce signalling compounds, which enable them to estimate
their population. When the concentration of these signalling compounds is too low, bacteria
simply proliferate in order to increase the population. The concentration of the signalling
compounds increases parallel to the bacteria population. When a critical concentration is
reached, the bacterial virulence increases significantly and infection or biofilm formation
occurs. This phenomenon is called quorum sensing.
3.2 Quorum sensing in Vibrio fischeri
3.2.1 Symbiose between Vibrio fischeri and the squid Euprymna scolopes
Vibrio fischeri is a Gram-negative bacterium which becomes luminescent at high cell
density. This bacterium can live in symbiosis with Euprymna scolopes, a small nocturnal
squid which lives in the shallow sand flats associated with coral reefs in the Hawaiian
archipelago [4.]
At night, predators can locate their preys through their shadows from the moonlight.
The bioluminescence of Vibrio fischeri enables Euprymna scolopes to camouflage itself by
8counter-illumination. It can control the intensity of the light it projects downward, so that it
can eliminate the visible shadow created by the moonlight.
3.2.2 Mechanism of bioluminescence in Vibrio fischeri
Eight different genes (luxA-E, luxG, luxI and luxR) encode the proteins that are
responsible for the bioluminescence system of Vibrio fischeri. In particular, the genes luxI and
luxR are responsible for the regulation of the bioluminescence. Beside these two genes, luxA
and luxB encode the synthesis of an heterodimeric luciferase, an enzyme which catalyses the
oxidation of an aldehyde and of reduced flavin mononucleotide. The reaction gives a long-
chain fatty acid, water and flavin mononucleotide. In addition the reaction produces an excess
of energy, which is liberated as blue-green light: this gives the bioluminescence. The other
genes luxC-E encode the compounds responsible for the synthesis of the aldehyde substrate,
which is used by the luciferase, and luxG encodes a probable flavin reductase.
3.2.3 Quorum sensing in Vibrio fischeri
At low cell concentration, the different lux genes are not active, therefore no
bioluminescence occurs. However, the bacteria produce an autoinducer, which is the N-(3-
oxohexanoyl)-L-homoserine lactone (OHHL, 17). This signalling compound can diffuse out
of the cell, as it can go very easily through the membrane. As bacteria proliferate, the
concentration of OHHL increases. When a critical OHHL concentration is reached, which
means that a certain cell concentration, also called quorum, occurs, the lux genes are activated
and the bacteria become luminescent (Figure 2).
At this critical concentration, the OHHL binds to the LuxR receptor, which probably
changes its conformation. Then it is supposed that the activated LuxR binds to a part of the
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9DNA chain, called lux box, and induces the transcription of other lux genes. Moreover, the
production of OHHL is amplified, which activates more and more the bioluminescence of the
population (Figure 2).
On the other hand, at low concentration of OHHL, the LuxR receptor induces the
transcription of luxR, but in higher concentration of OHHL, LuxR inhibits the transcription of
luxR. This property might be a regulating process that self-limits the autoinduction of
bioluminescence.
In addition to these processes, Vibrio fischeri produces N-octanoyl-L-homoserine
lactone (OHL, 18). This compound binds to LuxR competitively with OHHL, but contrary to
this latter, OHL inhibits the LuxR activation. At low cell concentration the inhibition of the
formation of the complex LuxR-OHHL prevents the premature induction of bioluminescence.
The gene that regulates the synthesis of OHL is called ainS and is completely independent
from luxI.
3.3 Quorum sensing and pathogens: the example of Pseudomonas aeruginosa
In the early 1990’s other Gram-negative bacteria showed regulatory systems
analogous to the LuxI-LuxR system of Vibrio fischeri. One of the most famous examples is
the quorum sensing system in the virulence of the pathogenic bacterium Pseudomonas
aeruginosa [5]. This bacterium is involved in tissues infections after wounds or at burn sites.
It is also responsible of chronic lung infections in patients who suffer from cystic fibrosis. The
strongest issue with this disease is that the chronic antibiotics treatment makes the bacterium
resistant, and the only way to avoid death of the patient is a lung transplantation. That is why
quorum sensing of Pseudomonas aeruginosa was widely studied during the last years.
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Figure 2: The regulation of bioluminescence in Vibrio fischeri: the quorum sensing system.
A. At low cell density, transcription of the genes for bioluminescence (luxICDABEG) is weak and
insufficient for the light emmission due to the low levels of OHHL.
B. At high cell density, a critical concentration of OHHL is reached. OHHL binds to LuxR and
stimulates transcription of luxICDABEG, leading to rapid amplification of the OHHL signal and
emission of light [4].
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The pathogenic activity of Pseudomonas aeruginosa consists in producing different
extracellular virulence factors such as proteases, haemolysins, exotoxin A, exoenzyme S and
pyocyanin. These compounds are responsible for the destruction of tissues in mammals, and
particularly in humans.
Two quorum sensing systems coexist in Pseudomonas aeruginosa (Figure 3). The first
system which had been described was the las system. The lasR gene encodes the receptor
protein LasR, which is activated by the N-(3-oxododecanoyl)-L-homoserine lactone (OdDHL,
19). In addition, the gene lasI encodes a synthase that is necessary for the OdDHL synthesis.
At a critical concentration, which occurs between the exponential growth and stationary
stages of the bacterium, the OdDHL binds to two LasR proteins, which activates the
transcription of the following genes: lasA, lasB, aprA, toxA, xcpR, xcpP, and lasI. The genes
lasA, lasB and aprA encode two elastases and an alcaline protease, which are all responsible
for tissue damages. The toxA gene encodes a toxin. The genes xcpR and xcpP encode the
production of proteins which enable all the compounds listed before to be excreted out of the
bacteria. Finally, the lasI gene enables a faster synthesis of the OdDHL, which amplifies the
quorum sensing.
The second system, called rhl, functions in a similar way (Figure 3). The gene rhlR
encodes the regulating protein RhlR, on which the N-butanoyl-L-homoserine lactone (BHL,
18) binds. The gene rhlI encodes the protein RhlI which enables the synthesis of the BHL.
Then the complex between RhlR and BHL induces the activation of several genes, such as
rhlAB, lasA, lasB, aprA, rhlI. It is also interesting to note that the las system can activate the
rhl system, because the OdDHL can either bind to LasR and RhlR proteins.
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Figure 3: Mechanism of quorum sensing in Pseudomonas aeruginosa [5].
4. Is it possible to inhibit quorum sensing?
It was observed by Kjelleberg and Steinberg that the red alga Delisea pulchra was
very rarely covered by biofilms [6,7], even when this alga grows in the presence of thousands
of bacteria species. The study showed that this alga was able to produce halogenated
furanones such as 22 and 23. These furanones show a structure, which is very similar to the
homoserine lactones seen above. Therefore, it could be assumed that the furanones produced
by the alga were able to interfere with the quorum sensing systems of different bacteria.
Moreover, it was seen for Vibrio fischeri that the bacterium was able to produce inhibitors of
its own quorum sensing system at low cell concentration [4]. It could be imagined that the
halogenated furanones have an analogous activity: the furanones could bind to the receptor
proteins in competition with the homoserine lactones, and by this way inhibit the activation of
the other genes responsible for the bacterial virulence.
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Following this idea, experiments were made by Hentzer et al. [8]. Their studies
showed that the halogenated furanone 23 gave a significant inhibition effect on the quorum
sensing systems of Pseudomonas aeruginosa. Although the furanone does not change the
growth rate of the bacteria, it reduces their virulence through the inhibition of the expression
of the genes responsible for it.
II Aims of the work
1. Natural furanones from Streptomyces antibioticus
Four natural furanones 24a, 25a, 26a, and 27a extracted from Streptomyces
antibioticus TÜ 99 showed a slight antibiotic activity as well as a slight inhibition effect on
chitinases from Serratia marcescens [9]. The furanone 26a, e.g., had a slight antibiotic
activity against Bacillus brevis and Arthrobacter oxydans. It was also active against
Pseudomonas fluorescens [10]. Similarly, the four furanones 24a, 25a, 26a, and 27a also have
antibiotic properties against the human pathogenic agent Pseudomonas aeruginosa [9].
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2. Natural furanones and quorum sensing
The natural furanones 24a-27a shown above have structures similar to the halogenated
compounds from Delisea pulchra, and also resemble somewhat the homoserine lactones from
quorum sensing systems of bacteria. The main idea was to synthesize new compounds that
could interfere with quorum sensing systems, and which are analogous to these natural
furanones.
As they were extracted in too small amounts, the furanones 24a-27a were chemically
synthesized in order to determine not only their chemical and biological properties, but also
their absolute configurations. A synthetic pathway was developed by Grossmann [11] in order
to have a convenient synthesis for larger amounts. This method was then applied to the
synthesis of new furanones [12].
3. The goals of the work
7KHNH\VWHSRIWKHV\QWKHVLVLVDFRQGHQVDWLRQRIWKHPHQWK\ODWHGIXUDQRQH38b and
an aldehyde to introduce a side chain at C(3) of the furanone. This step had to be optimized.
 7KH V\QWKHWLF SURFHGXUH GHYHORSHG E\ *URVVPDQQ VKRXOG EH XVHG WR REWDLQ
additional furanones with different side chains in position 3 of the lactone.
 7KH QHZ V\QWKHWLF IXUDQRQHV ZLOO KDYH WR EH WHVWHG LQ RUGHU WR LQYHVWLJDWH WKHLU
ability to inhibit the quorum sensing system of bacteria.
III Synthesis of the furanones
1. Overview of the method
A five step synthetic pathway was designed by Grossmann for the preparation of the
natural compounds 24a-27a [11]. The two step preparation of the menthylated furanone 38b
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had been previously described in the literature [13,14]. A Mannich-type reaction between
glyoxylic acid (28), propionaldehyde (29) and morpholinium chloride (30) affords the 5-
hydroxyfuran-2-one (37), which is menthylated under acidic conditions. A fractional
crystallization gives the pure 5(R) epimer 38b. This furanone is then added to 2-
methylpropanal or 2(S)-methylbutanal in the presence of LDA to give the respective epimer
mixtures 41a/b and 42a/b (Scheme 1). The isomers were separated by flash-chromatography
on silica gel. Then the menthyl ethers 41a, 41b, 42a, 42b were cleaved with BBr3 and the
obtained 5-hydroxy furanones 24a, 24b, 25a, 25b were reduced with NaBH4 to give the
compounds 26a, 26b, 27a, 27b. The absolute configurations of the natural products could
then be deduced from a comparison of their NMR spectra with those of the synthetic
compounds.
Scheme 1: Synthesis of the natural furanones 24a-27a and their enantiomers.
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2. First step: synthesis of the starting furanone (37)
Although this reaction was published in the early 80’s [13], its mechanism − being
particularly interesting − will be discussed in the following paragraph.
Scheme 2: Mechanism of 5-hydroxy-4-methyl-5H-furan-2-one (37) synthesis.
Morpholinium chloride (30) reacts with glyoxylic acid (28) to form the Mannich base
32 (Scheme 2), which reacts with the enol 31 corresponding to propionaldehyde (29).
Formula 33 shows the 6-membered ring transition state of this Mannich-like reaction.
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Condensation of both reagents with simultaneous departure of water gives the intermediate
34. Then an intramolecular cyclization occurs to 35, followed by an acid catalysed
rearrangement and elimination of the morpholine to afford the furanone 37.
3. Second step: the menthylation
At room temperature, the furanone 37 racemizes very quickly (Scheme 3). This
property makes the separation of isomers like 24a and 24b impossible, because one has to
deal with an equilibrium mixture of two pairs of enantiomers. Blocking the epimerization at
C(5) facilitates the separation of the epimers after the coupling with the aldehyde. The use of
a chiral blocking group could lead to chiral induction in the condensation of furanone and
aldehyde. (−)-Menthol is perfect for this purpose as it is a natural product, available in
enantiomerically pure form at a modest price. The menthylation of the starting furanone 37
was published by Feringa et al. at the end of the 80’s [14]. The reaction occurs in refluxing
toluene with p-toluenesulfonic acid as a catalyst, and the water which is produced during the
reaction can be collected in a Dean-Stark apparatus.
Scheme 3: Racemization of the furanone at room temperature.
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The reaction itself yields both epimers 38a and 38b, which can be separated through
fractional crystallization. After precipitation of both epimers at –18°C in petrol ether, the
wanted epimer 38b is isolated after successive recrystallizations from petrol ether.
4. Third step: nucleophilic addition of the furanone on the aldehyde
4.1 General remarks
The typical procedure was described by Grossmann. The condensation was first
performed at –78°C in dry THF. The furanone 38b was treated with LDA as a base to afford
the anion at C(3), then the aldehyde was added and the reaction carried out at –78°C.
Following these conditions, the reaction was tried with pivalaldehyde, heptanal and
decanal in order to obtain the respective compounds 47a, 47b, 50, 51. In fact, the tert-
butylated furanones 47a and 47b were obtained in poor yields (about 20% yield for the
mixture). Another product, 46, was isolated in significantly larger amounts, lacking the C(3)-
C(4) double bond according to the NMR spectra. Addition of heptanal or decanal  to the
furanone proved to be almost impossible under the above conditions (−78°C).
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4.2 Enolate reactivity
The crystallization of the new spiro-compound 46 followed by an X-ray structure
determination (Figure 4) revealed that the reaction conditions for the condensation were not
optimal. The structure showed that two equivalents of pivalaldehyde were added to the
furanone. How could this surprising result be explained?
Figure 4: X-ray structure of the spiro-compound 46.
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By treating furanone 38b with LDA, three different anions 38i, 38ii, and 38iii are
theoretically possible: with the negative charge on C(3) (38i), on C(5) (38iii), or on the
methyl carbon (38ii), respectively. In fact, the proton on the C(5) might not be acidic because
this position is a ketal function, and the corresponding anion should not be very stable.
Normally, formation of the anion is expected at C(3). However, the appearance of compound
46 clearly shows that the charge can also be formed at the methyl position. We assume that
the anion 38ii adds first to pivalaldehyde (Scheme 4), then the new anion 44 adds to a second
molecule of pivalaldehyde to form the intermediate 45. Then, cyclization via intramolecular
Michael addition occurs to give after protonation the observed spiro-compound 46.
Scheme 4: Hypothetical mechanism of the formation of 46.
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This mechanism explains reasonably well the observed result. The configuration of the
spiro carbon can be explained by steric consideration. The intramolecular Michael addition
will most likely take place from the side opposite to the menthyloxy group. In addition, the
tert-butyl groups are observed in equatorial positions. The main issue now was to figure out
how to promote anion formation at C(3).
In general with α,β-unsaturated ketones, the proton that is lost during the enolate
formation is located at the γ-carbon (vinylogous effect). So, we can assume that the
conjugated enolate 38ii should be more stable than the C(3) anion 38i. For this latter, the
negative charge is located in an electron rich area and almost no resonance stabilization is
possible. However, the C(3) anion 38i does exist, because condensation does occur at this
position. We conclude that the C(3) anion 38i is kinetically favoured, whereas the conjugated
enolate 38ii is thermodynamically more stable. This assumption led us to work at a lower
temperature. When the reaction is carried out at –100°C, no spiro-compound is obtained, and
the two expected epimers 47a and 47b were isolated in approximately 20% yield each.
The same procedure was applied for the condensation of the menthylated furanone
38b with heptanal 48 and decanal 49 to give the corresponding products 50 and 51 (Scheme
5) as mixtures of epimers in 30% (heptanal) and 37% yield (decanal), respectively. The lower
reaction temperature enabled in all the cases a very significant improvement of the yields. The
assumption about the kinetic behaviour of the C(3) anion was corroborated by these
experiments.
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Scheme 5: Condensation of 38b with heptanal and decanal.
4.3 Separation of the epimers
So far, the separation of the epimers formed in the condensation of the furanone with
the aldehyde could always be achieved by column chromatography on silica gel [12]. In this
way, pure diastereomers 47a and 47b could be obtained. Unfortunately, the epimers of the
compounds 50 and 51 could not be separated under these conditions.
5. Fourth step: cleavage of the menthyloxy bond
The classical ether cleavage reaction with BBr3 was used. In general, the Lewis acid
BBr3 is used for the cleavage of aryl methyl ethers, which allows very mild conditions. This is
particularly useful when the substrate contains a lot of functional groups and limits the risk of
a decomposition of the compounds.
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The mechanism of this cleavage is quite simple [15]. The oxygen of the ether adds to
the empty p-orbital of BBr3 (Scheme 6). Simultaneously, a bromide binds to C(5) of the
furanone, which is much more electrophilic than C(1) of the menthyl moiety. After work-up,
the respective alcohols are obtained. When the reaction was performed with 50, brominated
furanone 54 was isolated in addition to 53, which confirms the mechanism outlined above.
Scheme 6: Mechanism of the ether cleavage with BBr3.
The yield of this cleavage reaction is generally about 40-60%; the method was used
for the preparation of 52a, 52b, 53, and 55 starting from the respective menthylated
furanones.
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6. Fifth step: reduction of C(5)
The carbon C(5) can be reduced with NaBH4. The use of this hydride enables a
selective reduction, as it does not react with an ester, which is crucial for the synthesis of the
reduced furanones. The reaction occurs in methanol at room temperature, and the yields
generally range from 60% to 70%. Following these conditions, compounds 52a, 52b, 53, and
55 yielded the furanones 56a, 56b, 57, and 58, respectively (Figure 5).
Figure 5: Reduction of furanone C(5).
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The mechanism of the reduction of an aldehyde by NaBH4 involves a transition state
including the aldehyde, the BH4− anion and a molecule of the solvent [16]. In the present case,
C(5) is a hemiketal derivate. We can imagine a similar mechanism for its reduction. Since the
reaction occurs under basic conditions, part of the added NaBH4 reacts with methanol to give
methanolate ions, with hydrogen formation. Then the methanolate adds to BH4−, with
simultaneous hydride transfer to the furanone (Scheme 7). We suppose that the lactone ring
opens to promote this hydride transfer, but it could also be imagined that the hydroxy group
can leave C(5) without lactone opening. An opened lactone ring will reclose during the work-
up.
Scheme 7: Mechanism of the reduction with NaBH4.
7. Synthesis of MP133 (64)
This compound was obtained by Poncioni during the search for synthetic pathways to
furanones 26a and 27a [17]. The preparation of MP133 (64) was originally carried out
according to Demnitz’s method (Scheme 8) [18]. Heptanoic acid (69) was treated with
TMSCl under basic conditions to afford the corresponding ketene bis(trimethylsilyl) ketal
(70), which was condensed with 1-bromo-2,2-dimethoxypropane (71) under TiCl4 catalysis to
afford the β-methoxy-γ-bromo carboxylic acid (72). This latter was treated with DBU in
toluene to give furanone 64.
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Scheme 8: Preparation of MP133 (64) according to Demnitz’s method [17].
Interstingly, MP133 (64) proved to have a weak activity as A-factor analog in
Streptomyces pristinaespiralis [19]. However, the Demnitz method did not afford MP133 (64)
in sufficient yields, and more material was necessary for additional biological tests. As 64 is
also a flavour compound, a completely different synthesis of this furanone had already been
patented by Givaudan [20]: starting from acetylmethyl 2-bromoheptanoate, an intramolecular
Reformatsky reaction followed by a dehydratation gives 64.
Having elaborated in our group a versatile route to furanones (Grossmann’s method,
see above), we decided to try the latter for the synthesis of 64. The starting furanone 37 was
menthylated, but no fractional crystallization was performed. Both epimers 38a and 38b
(Scheme 8) were treated with LDA at –100°C and condensed with pentanal to give 60 as a
mixture of four diastereomers in 60% yield. Then, the menthyl group was removed with BBr3
to afford a mixture of two pairs of enantiomers 61 in 45% yield. All isomers of 61 were
reduced together with NaBH4 to give racemic 62 in 60% yield.
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Scheme 9: Towards MP133 (64) according the Grossmann’s method.
At this stage, an additional reduction was necessary to remove the OH group in the
side chain and give MP133 (64). A convenient general method to reduce secondary alcohols
is the preparation of a sulfonic ester followed by a nucleophilic substitution with a hydride. In
our case, a tosylation of 62 in pyridine (Scheme 10) to 63 and an immediate reduction of this
latter with NaBH4 after dilution in methanol gave the MP133 (64) in 43% yield [21].
Scheme 10: Reduction of 62 into MP133 (64).
The synthesis was performed with isomer mixtures as the final product MP133 (64) is
an achiral molecule. This avoids the loss of material, especially in the menthylation step with
the furanone 37: instead having to isolate a pure diastereomer in 15-20% yield, the non-
fractional recrystallization affords easily 50-60% yield of the mixture 38a/b. However, this
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menthylation step is necessary to avoid side reactions during the basic condensation with
pentanal.
In addition, in order to save a step, a double tosylation of both hydroxy groups of 61,
followed by the reduction with NaBH4 was attempted. However, these conditions did not
allow the direct preparation of MP133 (64) from 61.
IV Biological Tests, results and discussion
1. General remarks
Our synthetic furanones were expected to be analogues to natural homoserine lactones,
A-factor, and related compounds. Therefore, they might interact in two different ways with
the quorum sensing system. They can either promote or inhibit the quorum sensing
phenomena. This latter is more interesting, as it could prevent biofilm formation as well as
significantly reduce the virulence of pathogens.
2. Biological tests with Chromobacterium violaceum CV026
The bacterium Chromobacterium violaceum is able to produce a purple pigment called
violacein (68) which also has antibiotic properties. The biosynthesis of this pigment is
induced when a critical concentration of HHL (21) is reached in a similar way to triggering of
the bioluminescence of Vibrio fischeri.
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The wild-type bacterium is able to produce HHL, therefore a mutant strain of
Chromobacterium violaceum, called CV026, was used. This mutant is not able to produce
HHL, but it can synthesize violacein. This means that if HHL is added to the culture, then the
purple pigmentation is observed.
Figure 6: Structures of the tested furanones.
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The biological tests for quorum sensing interference were carried out with
C. violaceum CV026 and furanones from Delisea pulchra, flavouring furanones from
Givaudan, and the synthetic furanones mentioned above. Only the most significantly active
compounds, whose formula are given above (Figure 6), will be discussed further.
Two different experiments were made with the furanones. In the first experiment, the
furanone and HHL were added simultaneously to the mutant bacterium. The absence of the
purple coloration meant that the tested furanone was able to inhibit the quorum sensing
system, whereas the apparition of the coloration proved the furanone was not active in this
way. The second experiment consisted in adding only the furanone to the bacterium. The
coloration meant that the furanone could work in a similar way to HHL, whereas no
coloration meant that the furanone had no effect.
As an example, the complete activity tests for compound 52b are given. Figure 7
shows the bioassay plate. The concentration of the furanone 52b decreases horizontally from
1 to 12 and the concentration of HHL decreases from row A to F. For each concentration,
three tests were made. E.g., the samples A1, A2, and A3 contain the same mixture.
We explain here the conditions for the tests. The concentrations of the furanone were
10−2 M in columns 1 to 3, 10−3 M in columns 4 to 6, 10−4 M in columns 7 to 9, and 10−5 M in
columns 10 to 12. The concentrations of HHL were 10−6 M in row A, 3.3*10−7 M in row B,
1.1*10−7 M in row C, 3.7*10−8 M in row D, 1.2*10−8 M in row E, and 4.1*10−9M in row F.
The calibration with HHL alone was made with the following concentrations: 10−6 M in G1-
G3, 10−7 M in G4-G6, 10−8 M in G7-G9, 10−9 M in G10-G12, 10−10 M in H1-H3, and 10−11 M
in H4-H6. A growth control of the mutant CV026 lacking HHL was made in H7-H9, and the
growth inhibition was tested with the bacteria in the presence of 52b at 10−2 M in H10-H12
[22]. Quorum sensing inhibition was measured by absorbance at 590 nm after evaporation and
resolubilization in DMSO of the samples, and growth inhibition (or activation) was measured
by turbidity at 660nm.
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At maximal concentration of 52b (A1-F1), no purple coloration was observed: this
showed that the quorum sensing was completely inhibited. In addition, the purple coloration
became stronger with decreasing furanone concentration indicating decreasing inhibition (e.g.
A1-A12). Full development of the purple coloration was observed for the HHL calibration
samples, where no furanone was added (G1-G12, H1-H6). The colourless samples H7-H12
corresponded to the growth inhibition test.
Figure 7: Bioassay for quorum sensing demonstrating effects of 52b on violacein formation
[22].
Similar series of tests were made with the other furanones. The results are summarized
in Table 1, while all compounds tested are compiled in Figure 6. Activation of quorum
sensing is shown in the second column; growth control = 0 and 3.7*10−8 M HHL = 100. In the
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third column, the growth activation is given; growth control = 100, significant activation
(>115) is emphasized in bold green and significant toxicity (<60) in bold red. In the fourth
column, the inhibition of quorum sensing is given for HHL at 3.7*10−8 M and compound to
be tested at 10−4 M: control = 0 and complete inhibition = 100. Significant inhibitions (>40)
are emphasized in bold red. The fifth column also gives inhibition properties: HHL
concentration is 10−6 M and compound concentration is 10−4 M. Significantly better inhibition
effects compared to the fourth column are given in bold red, whereas significantly smaller
effects are given in bold green. The change in activity is considered as significant when the
difference is more than 15. The sixth column gives the synergistic effect of the tested
compounds at 10−5 M with HHL at 4.6*10−9 M: control = 100, and significantly enhanced
expressions (>115) are given in bold green.
Compound Activation Growth
activation
Inhibition 1 Inhibition 2 Synergistic
effect
22
−4 59 68 61 96
24a
−1 96 31 55 121
24b 0 97 69 82 18
25a −2 75 27 46 127
25b −2 83 17 5 241
26a −5 65 64 64 52
26b −1 86 42 33 94
27a −3 72 26 48 164
27b −3 76 34 49 137
37
−4 65 22 23 174
52a
−8 38 49 72 105
52b
−5 50 80 64 82
55
−6 52 13 6 115
56a
−4 53 53 49 90
56b −6 49 56 68 86
58 3 117 30 2 97
Table 1: Effects of the furanones on quorum sensing and growth [22].
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3. Discussion
Even if some of the tested compounds proved to be toxic at 10−2 M, such as 52a, 52b,
55, 56a, and 56b, none of them inhibited cell growth at 10−4 M. As the tests were made at this
concentration, or at a lower one, we can assume that the results are only due to the interaction
between the compounds and the quorum sensing system.
Only the furanone 65 activated the quorum sensing without HHL. It is also not
surprising to notice that the DHL (66) strongly activates the formation of violacein [22].
The halogenated furanone 22 extracted from Delisea pulchra significantly inhibits the
violacein formation. In addition, this furanone is toxic as it also reduces the bacterial growth.
This result is in accordance with the observation in nature: the red alga Delisea pulchra is
rarely covered by biofilms. It confirms that halogenated furanones are able to inhibit the
quorum sensing in nature.
Furanones 24b and 26a showed quite good inhibition. The furanone 24b is not toxic,
as the growth activation was not significantly different from the control, whereas the
compound 26a showed a slight toxicity at 10−2 M. The most active compounds were the
furanones 52a, 52b, 56a, and 56b. For these compounds, the inhibition of violacein
production ranged from 49% to 80%. All these compounds are derived from the condensation
of the menthylated furanone 38b with pivalaldehyde. Furthermore, these compounds proved
to be toxic for bacteria, as they inhibited the growth from 48% to 62%. It shows that these
derivatives not only inhibit the quorum sensing but also disable the bacterial proliferation at
higher concentration. Compared with the halogenated furanones from Delisea pulchra, the
compounds 52a, 52b, 56a, and 56b have similar bioactivities.
O
O
OH
O
O
H
N
O
65 66
34
The natural furanones as well as the synthetic compounds from Grossmann have quite
short side chains: this is an important difference to the structures of the homoserine lactones.
A longer side chain at C(3) should resemble in a better way the homoserine lactone structure.
The derivatives 55 and 58 were synthesized following this idea: it was supposed that the
biological activity could have been improved by the introduction of a long aliphatic chain at
C(3). Unfortunately, furanones 55 and 58 showed very poor inhibition effects.
Some of the furanones showed a synergistic effect with HHL. E.g. 25b and 65 at
10−5 M concentration activated the violacein (68) production two times better than HHL alone
at 4.6*10−9 M. Approximately half of the compounds tested led to an enhanced violacein
production.
The results show, that it is not possible to class the compounds tested in agonists or
antagonists of the quorum sensing receptors. In addition, there is a competition between these
compounds and HHL to the binding sites of the receptors.
A comparison of compounds 24a and 26b with their respective epimers 24b and 26a
shows significantly different activities. The furanones 24a and 26b are less active than their
respective epimers. In contrast, the enantiomers 56a and 56b have similar activities, even if
56b is a bit more active at higher HHL concentration.
Thus, it is very difficult to find a relationship between the structures of the synthetic
furanones and their activities. Therefore it is not possible to predict which structure would
have the best effect. There is for instance no correlation between the configuration of the
carbon bearing the secondary alcohol in the side chain and activity in the quorum sensing
system.
3. Biological activity of MP133 (64)
In a former study, MP133 (64) had been tested with a protein from Streptomyces
pristinaespiralis. This protein is a receptor, which is involved in the pristinamycin
biosynthesis. Natural butyrolactones bind to this receptor, which induces the antibiotic
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production. MP133 (64) showed an ability to weakly inhibit this binding to the receptor
protein [19].
According to these results, the biological activity of MP133 (64) was investigated
further with mammalian cells. The aim was to test a possible activity on gene regulation in a
similar way with the quorum sensing of Streptomyces. However, the compound proved to be
toxic: it significantly inhibited the cell growth [21].
V Conclusion
The procedure developped by Grossmann [11] enables the synthesis of a large family
of furanones in moderate yields through simple reactions, and it was successfully used for the
preparation of furanones containing longer side chains. The reduction of the secondary
alcohol in the side chain is also possible. However, the separation of the epimers after the
condensation of the menthylated furanone and a long chain aliphatic aldehyde remains
difficult. On the other hand, the yield of this condensation could be significantly improved by
the use of new reaction conditions.
Some of the compounds we had prepared proved to be biologically active. They
inhibited more or less the quorum sensing of Chromobacterium violaceum CV026. A few of
these inhibitors also showed toxic properties since the growth of the bacteria was reduced in a
significant manner. However, none of the synthetic furanones was significantly more active
than the natural halogenated furanones from Delisea pulchra.
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Part two:
Substituted furanones as putative chitinase inhibitors
I Introduction
1. Glycosidic biopolymers
In the living world, the most abundant polymers that we can find are carbohydrate
derivatives. These glycopolymers can be found in a large variety of structures and for very
different purposes. The best known glycopolymers are cellulose, starch, chitin and glycogen.
Cellulose is the most important material for the plant cell walls. It is a linear polymer
of glucose. The monomers are linked through a beta 1-4 glycosidic bond. The linear chain
could be very flexible if there were no hydrogen bond interactions between monomers. In the
same way, inter-molecular hydrogen bond interactions make the structure rigid. Cellulose
polymers linked together can arrange themselves in sheets, which are very resistant. Then,
cohesion forces between the sheets gives hydrophobic properties, as well as more rigidity. So,
the formation of micro-fibrils can occur, and this enables the production of a very resistant
material.
Starch is also a polymer of glucose. The main difference to cellulose is that there are
ramifications in the polymer structure. Starch is a convenient way for plants to store large
amounts of energy. Therefore cereals and potatoes, which are rich in starch, are very
energizing food.
Animals are also able to store large amounts of energy through the polymerization of
glucose: they produce glycogen. This glycopolymer, like starch, is a ramified polymer of
glucose. The difference to starch is the number of ramifications. In glycogen, this is much
more important than in starch.
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Chitin is different: the monomer is N-acetylglucosamine. Chitin is the most abundant
polymer containing nitrogen in the living world. The structure is analogous to cellulose: chitin
is a linear polymer in which the monomers are linked through beta 1-4 glycosidic bonds [23].
Like cellulose, chitin can form sheets in order to assemble itself in very rigid structures like
insect exoskeletons or crustacean shells. In addition, chitin can be found in the cell wall of
micro-organisms such as bacteria, mushrooms, fungi, and yeasts.
2. Glycosidases
The biosynthesis of the polymers involves very complicated processes. The enzymes
used for the synthesis, as well as the degradation must have the suitable selectivity. We can
imagine that there are as many different glycosidases as animal or plant species in nature. In
fact, it is possible to classify the different enzymes in several families. Such a classification
has been introduced by Henrissat [24-26]. All chitinases, the enzymes which are mainly
responsible for chitin degradation, are classified into families 18 and 19.
3. Different roles of chitinases in nature
Chitinases are essential in chitin metabolism processes. They enable the regulation of
the insect exoskeleton formation, as well as the degradation of chitin. As chitin is too rigid to
enable the growth, insects have to change their exoskeleton regularly. This process is the
moulting. The exoskeleton is degraded in certain parts so that the insect can get rid of it: it is
precisely during this moment that chitinases are crucial. Then insects need several days to
grow a new exoskeleton that fits their new size.
Chitin is also an essential constituent of the membranes of bacteria and mushrooms,
including in particular pathogenic bacteria and different species of parasites. Unlike animals,
plants have no immune system, therefore chitinases are useful for plants to fight pathogens
through the destruction of their cell wall: thus chitinases are defence proteins. In the same
way, animals also produce chitinases as well as lysozymes in addition to their immune
system: these enzyme are complementary to the immune system in order to prevent
infections.
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Furthermore, chitinases are used by predators and carnivore plants. They enable the
digestion of their preys. E.g., the octopus Eledone cirrhosa generally eats crabs. It injects its
saliva, which contains a potent mixture of chitinases and proteases into its preys. The saliva
diffuses throughout the prey (the crab) and enables the predator to remove the meat from the
carapace [27]. Some parasites can also produce chitinases to enable them to penetrate into an
insect’s body. In addition, chitinases also provide nutrients to the parasites, since the insect
exoskeleton can be hydrolysed into glucosamine derivates. Moreover, the chitinases can
participate to the release of progeny pathogens.
These examples of the uses of chitinases in nature are not exhaustive, but they show
some of the most important functions of these enzymes.
4. General information on chitinases
Chitinases are proteins whose molecular weights range from 30 kDa to 120 kDa. Plant
and alga chitinases have generally a molecular weight of 30 kDa. Chitinases from animals
such as mollusks, arthropods, fishes, amphibians and mammals have molecular weights
generally from 40 to 90 kDa, and some of them can be up 120 kDa. Bacterial and fungal
chitinases have very different sizes, ranging from 30 kDA to 120 kDa [28].
 The optimum activity occurs generally at an approximately neutral pH, or under very
mild basic conditions as well as slightly acidic conditions. Plant and algal chitinases are active
between pH 4 and pH 9. Chitinases from animals are best active at pH 4.8-7.5, whereas
chitinases from microorganisms are active at pH 3.5-8.0.
It was possible to isolate chitinases from Bacillus licheniformis in hot springs. These
chitinases were stable at 80°C. Other chitinases from plants also showed such thermal
stability. On the other hand, chitinases from insects are much less stable at high temperature.
For instance, chitinases from silkworm are unstable above 40°C. In fact, most of time, insects
use chitinases for the production and the degradation of their exoskeleton. As they generally
grow at moderate temperature, like 25°C, they do not need chitinases, which are stable at high
temperature. In addition, chitinases from insect are generally larger than chitinases from
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plants. It can be assumed that smaller chitinases are more stable at higher temperature than the
bigger ones.
There are two different catalysis mechanisms for the hydrolysis of chitin: the catalysis
with inversion of the configuration of the anomeric carbon of monomers and the catalysis
with retention [29].
Figure 8: Cleavage of a β-glycosidic bond with retention of the anomeric configuration [29].
Figure 8 shows the mechanism of the degradation of chitin with retention of
configuration of the anomeric carbon. The glycosidic bond breaks with a simultaneous
protonation of the leaving alcohol. The oxocarbenium cation obtained is stabilized in the
active site by carboxylate anions (e.g. from glutamate). Then, water adds to the intermediate
to complete the cleavage.
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Figure 9: Cleavage of a β-glycosidic bond with inversion of the anomeric configuration [29].
The mechanism with inversion of the configuration gives the α-anomer (Figure 9). In
this case, the mechanism resembles an SN2 reaction. This mechanism is illustrated by the
chitin degradation by a barley chitinase (Figure 13). The chitin fragment is maintained in the
active site through hydrogen bonds (Figure 10). The glutamic acid (Glu 67) activates the
oxygen of the leaving sugar. At the same time, the glutamate (Glu 89) polarizes water, which
adds to the anomeric carbon.
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Figure 10: Hypothetical binding and cleavage of a chitin polymer with barley chitinase [29].
Both mechanisms presented above remain hypothetical. They are, however, in
accordance with the configuration observed in the products. The inversion mechanism was in
addition confirmed by NMR and kinetic studies [30].
5. Classification of chitinases
 Henrissat and Bairoch developed a classification for all the glycosidases [24-26]. This
classification is based on the amino-acids sequences of the proteins. It led to define more than
50 different families of glycoside hydrolases. As a consequence of this, two proteins from the
same family have close structures and have similar hydrolysis mechanisms. Though chitinases
are widely present in nature, they all belong to only two families: the family 18 and the family
19.
The family 18 is the largest family with approximately 180 members. It contains
essentially chitinases from eukaryotes, prokaryotes and viruses. The family 18 chitinases have
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an α/β barrel structure, in which the active site is located in the centre of the barrel. A
structure analysis of the chitinase from Serratia marcescens (Figure 11) shows that the barrel
is constituted of β-sheets, linked by return α-helices. Hevamine (Figure 12), a defence protein
from the rubber tree Hevea brasiliensis, is also a family 18 chitinase, and has a structure close
to that of the chitinase from Serratia marcescens. The catalysis mechanism of family 18
chitinases is with configuration retention with a double displacement mechanism, as discussed
above [29].
Figure 11: Structure of a chitinase from Serratia marcescens [29].
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Figure 12: Structure of hevamine [31].
Family 19 is smaller: about 130 members are listed in this category. The family 19
chitinases were all extracted from plants, except a chitinase from Streptomyces griseus. The
structure of these chitinases is essentially built from α-helices [29] like in the barley chitinase
(Figure 13). The catalytic mechanism is with a configuration inversion. This explains the
strong structural difference to the family 18 chitinases.
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Figure 13: Structure of barley seed endochitinase (stereo view) [32].
6. Inhibitors of chitinases
Inhibitors are very useful to study the catalytic mechanism of enzymes. Furthermore,
vertebrate do not produce chitin, so interfering with the chitin metabolism can be a suitable
method to develop insecticides that are non-toxic for humans. Chitin synthesis inhibitors, e.g.
diflubenzuron (73, Dimilin®), have been used in this way for more than 20 years [23, 33].
The main issue when developing chitinase inhibitors as insecticides is the selectivity.
Plants as well as animals have pathogen defence chitinases. Therefore, the new chitinase
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inhibitors have to be active against insect chitinases only: a non-selctive chitinase inhibitor
would weaken plant and animal defences.
Spindler (University of Ulm) published several articles concerning chitinase inhibitors.
It was shown that metal cations such as Cu2+, Zn2+, or Hg2+ could inhibit chitinases,
particularly those of bacteria and of some insects [34]. Some plant chitinases were also
inhibited by such divalent cations. However, other metal cations, such as Na+, K+, Ca2+, or
Mg2+ activated the chitinase from the marine bacterium Alteromonas.
Some cyclic peptides showed interesting properties. Cyclo(L-Arg-D-Pro), isolated
from marine Pseudomonas sp. showed an activity against chitinases from Bacillus sp.,
Saccharomyces, and Candida. [34]
Other compounds called styloguanidins (74a-74c) were extracted from the marine
sponge Stylotella aurantium and showed an activity against a chitinase from Shewanella sp.
Up to date, the inhibitory properties of the styloguanidins were not completely elucidated.
[34]
The most famous chitinase inhibitor is allosamidin (75). It was isolated from
Streptomyces sp. by Sakuda et al. [35]. Allosamidin essentially inhibits family 18 chitinases,
and particularly chitinases from insects. This good selectivity enables the development of a
new generation of insecticides. However, allosamidin is not suitable for a commercial use,
since the total synthesis is too expensive to allow an industrial production [36], and the
compound is not stable under field conditions.
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II Aims of the work
1. Conditions for the development of allosamidin analogs
Allosamidin was first isolated, and the structure elucidated, by Sakuda et al. from
Streptomyces sp. [35]. A mycelial extract of Streptomyces sp. inhibited significantly
chitinases from the silkworm Bombyx mori.
Allosamidin is a pseudo-trisaccharide, whose structure contains two main parts: an
allosamine disaccharide, and an aminocyclitol derivative called allosamizoline. The
allosamine disaccharide has a structure which is very close to that of chitobiose, the dimer
obtained after the degradation of chitin: this might be the recognition part. On the other hand,
the allosamizoline moiety has a structure which differs from chitin much more than the
allosamine part: this might be the inhibition part.
According to these assumptions, and after testing different inhibitors, Spindler
concluded that good chitinases inhibitors must contain at least one glucosamine moiety, and
the compound must mimic the spatial arrangement of the allosamizoline part [34].
2. Activity of menthylated furanones
Preliminary tests showed that the natural furanones 24a-27a, in addition to their
antibiotic properties, were also weak chitinase inhibitors [9]. These compounds were
synthesized to get more material for further investigation of their biological properties. The
synthetic furanones, as well as all intermediates, were tested as potential chitinase inhibitors
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by Spindler (University of Ulm). Surprisingly, the natural compounds proved to be inactive,
whereas some menthylated intermediates were active.
The furanones were tested with four different chitinases: chitinases A and B from
Serratia marcescens, a chitinase from Chironomus tentans, and a chitinase from Hevea
brasiliensis. We give here the most significant results for the chitinase B from Serratia
marcescens with methylumbelliferyl-chitobiose (MUF-chitobiose) as substrate [37] (Figure
14, Table 2).
Figure 14: Inhibition of chitinase B from Serratia marcescens by furanones 41a, 41b, 42a,
42b, with MUF-chitobiose as substrate.
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Compound 41a 41b 42a 42b
IC50 (µM) 170 280 100 190
Table 2: IC50 values estimated from Figure 14. Inhibition of chitinase B from Serratia
marcescens by furanones 41a, 41b, 42a, 42b, with MUF-chitobiose as substrate.
It is noteworthy that the compounds 41a and 42a are significantly more active than
their respective epimers 41b and 42b. In addition, compound 42a is more active than 41a.The
same is true for 42b and 41b when the IC50-values are compared. However, the latter
compound is more active at higher concentration. The S-configuration of the secondary
alcohols in the side chain of the furanones seems to give a better inhibitory effect to the
compounds, in comparison to the respective epimers.
3. Glycosylated furanones
The activity of the furanones listed above could be explained as follow: the structure
of the mentylated furanone could be analogous to the allosamidin. In fact, we could assume
that the menthyl group, with its 6-membered-ring, should be analogous to a monosaccharide
like glucosamine. The substituted furanone on the other hand could mimic the allosamizoline
moiety of allosamidine.
Therefore, it can be hoped that if the menthyl group is replaced by a saccharide, then
the inhibitory activity of the compound should increase. The goal of the work therefore was to
link to the furanone a carbohydrate through a suitable glycosylation method in order to obtain
a new family of glycosylated furanones, which could be inhibitors of chitinases.
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III Synthesis of glycosylated furanones
1. Ideas for the synthesis
The main purpose was to develop the simplest synthesis possible. The use of acetates
as protecting groups for the glycosides should be a good idea, since the selective anomeric
deprotection of acetylated sugars is very simple and gives generally good yields. The removal
of acetyl groups should also be facile.
However, the C(5) configuration of the furanone after glycosylation cannot be
predicted. In contrast, depending on the glycosylation method, it should be possible to obtain
selectively the α- or β-anomer. In this way, two mixtures of C(5)-epimers would be obtained.
If the stereoselective glycosylation is not possible, a mixture of four diastereomers will result:
The biological activity of the isomer mixtures should be investigated. If an inhibitory
effect is observed, the separation of the diastereomers should be carried out in order to
identify the active isomer.
2. Preparation of the starting materials
The starting monosaccharides 77 and 81 are very simple to prepare in relatively good
yields (Scheme 11). The tetraacetylated glucose 77 is obtained after selective cleavage of the
ester at the anomeric center, with ethanolamine and DMSO in AcOEt, from the commercially
available peracetylated glucose 76 [38]. This reaction gives compound 77 in 80% yield. The
tetraacetylated glucosamine 81 is prepared from N-acetyl-D-glucosamine (78) in two steps.
After acetylation with AcCl and chlorination of the anomeric position [39], the intermediate
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79 is hydrolysed with NaHCO3 in MeCN. This hydrolysis can also be performed with
Ag2CO3 [40] so that the chloride is removed as AgCl, but the use of NaHCO3 is much cheaper
and gives the same yield.
Scheme 11: Preparation of the starting monosaccharides 77 and 81.
The acetylation of the glucosamine 78 is performed in a sealed flask, so that the
hydrogene chloride, which is produced during the acetylation cannot escape and in situ
replaces the anomeric OH to give 79. If the hydrogen chloride is removed from the reaction,
the exclusive formation of the peracetylated glucosamine 80 is observed. However, even in a
sealed apparatus a small part of peracetylated glucosamine 80 was formed.
The acetylated disaccharides 83 and 85 were also prepared (Scheme 12). Commercial
cellobiose octaacetate 82 was selectively deacetylated at the anomeric position with hydrazine
acetate in DMF to give 83 in 89% yield [41,42]. Chitobiose octaacetate 84 was prepared by
degradation of chitin with sulfuric acid and acetic anhydride [42], or by enzymatic
degradation with chitinase from Streptomyces griseus [43] followed by acetylation with acetic
anhydride. The octaacetate 84 was selectively deacetylated et the anomeric position to give 85
in 61% yield.
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Scheme 12: Preparation of the starting disaccharides 83 and 85.
3. Glycosylation
The most common methods for the synthesis of oligosaccharides are the use of
halogenated carbohydrates, trichloroacetimidate derivatives, and thioglycosides. The use of
halogenated carbohydrates as glycosyl donors was described by Koenigs and Knorr in 1901
[44,45]. The glycosylation is performed in the presence of a heavy metal salt in order to
activate the halogenated carbohydrate (Scheme 13). For instance, a silver salt is often used as
the silver chloride precipitates and the reaction is favoured by this way. In fact, the departure
of the halide from the anomeric position of 86 gives an oxocarbenium cation 87, which reacts
with an alcohol to give the glycoside 88. However, a Lewis acid can also be used to replace
the heavy metal salt.
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Scheme 13: Koenigs-Knorr glycosylation.
In addition, the reactivity of the glycosyl halide depends on the protecting groups of
the glycosyl donor. For instance, ether protected carbohydrates are generally more reactive
than the analogous ester protected ones. Furthermore, the protecting group at O-C(2) is of
highest importance, as it gives a neighbouring group effect. The best example is the
acetamido group, which can form an oxazoline after departure of the anomeric halide.
A more recent glycosylation method was designed by Schmidt [46]. The anomeric
position is activated through the formation of a trichloroacetimidate. This trichloroacetimidate
can be easily prepared by the treatment of the glycoside with a base, such as NaH or DBU,
and trichloroacetonitrile (Scheme 14). The resulting trichloroacetimidate can be isolated and
stored under anhydrous conditions. It is activated for glycosylation by a catalytic amount of a
Lewis acid, such as trimethylsilyl triflate (TMSOTf) or boron trifluoride-diethyl etherate
(BF3Â(W2O) at low temperature.
Scheme 14: Schmidt glycosylation.
Thioglycosides are another convenient way to synthesize new glycosidic bonds [47-
49]. They can be prepared very easily by the treatment of the corresponding glycoside with a
mercaptan, in the presence of a Lewis acid:
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An alternative method is the treatment of the glycosyl halide with a mercaptide, which
also gives good yields. The main interest of these thiocompounds is their stability. The
anomeric thioether is compatible with various reaction conditions.
The activation of thioglycosides occurs with soft electrophiles (Scheme 15). The most
commonly used reagents are methyl triflate (MeOTf) and dimethyl(methylthio) sulfonium
triflate (DMTST), for instance. The electrophilic activator reacts with a lone pair of the sulfur.
The resulting sulfonium intermediate is an excellent leaving group. Then, addition of an
alcohol can lead to the glycosylation.
Scheme 15: Activation of thioglycosides with soft electrophiles.
Activation of thioglycosides is also possible by treatment with tris-(4-
bromophenyl)ammonium hexachloroantimonate (TBPA+•). In this case, a one-electron
transfer occurs (Scheme 16), leading to a sulfonium radical cation. The thioglycoside is
cleaved into an oxocarbenium ion and a sulfur radical, which dimerizes into a disulfide.
Glycosylation is achieved by addition of an alcohol on the oxocarbenium ion.
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Scheme 16: Activation of thioglycosides by one-electron transfer.
3.1 Searching for the best method
A first attempt to achieve the glycosylation was made with the halogenated
glucosamine 79 and the furanone 37 in the presence of ZnCl2 as Lewis acid (Scheme 17)
[50,51]. No reaction occurred under these conditions. Then, the coupling between the
acetylated glucosamine 81 and the furanone 37 was tried in refluxing toluene in the presence
of p-toluenesulfonic acid, in analogy to the menthylation of the furanone. As there was
degradation of the carbohydrate, the same reaction was also tried at room temperature, which
remained again unsuccessful. The use of DCCI [52] as the coupling reagent did not give the
expected compound 96.
Scheme 17: Unsuccessful glycosylations with glucosamine derivatives.
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As these methods gave no positive results, it was decided to first elaborate a synthetic
method for 92 using the acetylated glucoses 76 or 77, which are much cheaper than the
acetylated glucosamine 81. The glycosidation was tried under basic conditions. The furanone
37 was treated with the glucose pentaacetate 76 in the presence of DBU (Scheme 18). The
same reaction was also carried out with the acetylated glucose 77, the furanone and DBU,
then NaH was used as the base. None of these reactions under basic conditions led to the
desired products.
Scheme 18: Unsuccessful glycosylations with acetylated glucose derivatives.
It was decided to prepare the brominated furanone 90, in order to make C(5) more
electrophilic. This halogenated compound was synthesized by reducing the starting furanone
37 with NaBH4 in 81% yield to 89 (Scheme 19) [53], which was then brominated with N-
bromosuccinimide and light in 85% yield to give 90 [54]. The glycosylation was tried with 90
and tetraacetyl glucose (77) with NaH as the base, but no glycosylated furanone 92 could be
isolated.
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Scheme 19: glycosylation attempt with a brominated furanone.
3.2 The Schimdt glycosylation
As direct glycosylation gave no result, the activation of the glucose through the
preparation of the trichloroacetimidate 91 was performed (Scheme 20) [46]. This
trichloroacetimidate was treated with the furanone 37 and BF3Â(W2O [55] to afford the
expected glycosylated furanone 92 in 38% yield.
Scheme 20: Preparation of 92 by Schmidt glycosylation.
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The same product 92 could be obtained in 70% yield in a “reversed type Schmidt
reaction” [56,57] with the acetylated glucose 77 and the furanone 93 (Scheme 21), which was
activated as the trichlororacetimidate. This latter was prepared by the treatment of the
furanone 37 with trichloroacetonitrile in the presence of NaH [37]. The glycosylation was
performed with either BF3Â(W2O or TMSOTf as the Lewis acid.
Scheme 21: Synthesis of 92 by “reversed type Schmidt reaction”.
As the Schmidt glycosylation works with glucose derivatives, it was tried with
glucosamine derivatives. The acetylated glucosamine 81 was transformed to the
corresponding trichloroacetimidate 94, which then was reacted with the furanone 37 using
BF3Â(W2O as the Lewis acid. Unfortunately, the expected glycosylated product 96 was not
obtained, but only the oxazoline 95 (Scheme 22) [58]. However, when the “reverse Schmidt
glycosylation” was performed with the acetylated glucosamine 81 and the furanone
trichloroacetimidate 93, using TMSOTf as the Lewis acid, the expected product 96 was
obtained in 42% yield.
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Scheme 22: Preparation of 96.
Similarly, the glycosylation of the acetylated cellobiose 83 yielded under analogous
conditions the product 94 in 64% (scheme 23). In this preparation, the furanone 93 and the
Lewis acid were used in larger excess than for monosaccharide glycosylation. Application of
the same procedure to the acetylated chitobiose 85 did not afford the desired glycosylated
furanone 98.
Scheme 23: “reverse Schmidt glycosylation” with acetylated cellobiose and chitobiose.
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3.3 Discussion of the mechanism
The formation of the trichloroacetimidate is a base-catalyzed addition. Acetylated
glucose 77 reacts with NaH (Scheme 24). The obtained alcoholate 77i adds to
trichloroacetonitrile to form the intermediate 91i, which reacts with 77 in an acid-base
reaction to give the trichloroacetimidate 91.
Scheme 24: Mechanism of the formation of the trichloroacetimidate 91.
It was mentioned above that the menthylation of the starting furanone 37 gave two
epimers differing in the configuration at C(5) of the furanone. There was no configuration
change at C(1) of the (−)-menthol, which shows that the C(5) of the furanone is electrophilic:
this is not surprising because this carbon is a ketal. The p-toluenesulfonic acid activates the
OH group, which is normally a very bad leaving group (Scheme 25).
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Scheme 25: Acid catalyzed menthylation of 37.
On the other hand, the C(5) hydroxy group of furanone 37 has weak nucleophilic
properties and thus can be added to the glucose trichloroacetimidate 91, with the displacement
of the trichloroacemidate in a “normal” Schmidt glycosylation. In addition, there is a
neighbouring group assistance (Scheme 26), which promotes the formation of the β-
glycoside. The same process does not occur with the stable oxazoline 95 (Scheme 22),
showing that the furanone is not a strong enough nucleophile to open the oxazoline ring.
Scheme 26: Mechanism of the Schmidt glycosylation with 91.
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The “reverse Schmidt glycosylation” functions in a similar way. The
trichloroacetimidate 93 is activated by the Lewis acid (e.g. BF3Â(W2O) and the acetylated sugar
(e.g. 77 or 81) adds to the C(5). This confirms the electrophilic properties of the C(5) of the
furanone.
3.4 Stereochemistry
The “reversed Schmidt glycosylation” does not enable a selective formation of α or β
anomers. As the addition of the sugar can occur on both sides of the furanone giving both
epimers at C(5), all products can only be obtained as mixtures of four diastereomers..
The four stereoisomers of furanone 92 derived from acetylated glucose could not be
fully separated by column-chromatography on silica gel. Nevertheless, one of the isomers
(92a) could be isolated. In the proton NMR spectra, the signal observed for the anomeric
proton was a doublet with a coupling constant equal to 8 Hz. Such a coupling constant is
typical for the diaxial arrangement of the anomeric proton and H-C(2) in β-anomers. In α-
anomers typically a coupling constant of about 4-5 Hz is observed.
The configuration of the furanone C(5) of 92 could not be determined by NMR
analyses. The only way to elucidate it would be an X-ray structure determination, but
unfortunately no suitable crystal could be obtained.
The four diastereomers 96a, 96b, 96c, and 96d of furanone 96 derived from acetylated
glucosamine could be partially separated by column-chromatography on silica gel, with a
slow gradient of MeOH in CH2Cl2. Some fractions contained two or more isomers. For each
isomer, the anomeric configuration was determined by NMR. One of the two α-anomers
could not be purified properly: the sample contained significant amounts of other isomers.
The yields obtained of each isomer are give in Figure 15.
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Figure 15: Separation of isomers of 96.
Only for one of the four isomers (96d) a crystal suitable for X-ray structure
determination was obtained. The structure derived from this measurement is shown in Figure
16. Since NMR spectra showed that 96c was the epimer at furanone C(5) of 96d, its structure
could be deduced. However, the configuration of furanone C(5) of 96a and 96b could not be
elucidated.
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Figure 16: Crystal structure of 96d.
The reaction of the acetylated cellobiose 83 with the trichloroacetimidate 93 gave also
a mixture of four diastereomers 97 which could not be separated. Only one α-isomer could be
concentrated enough by chromatography to allow for an NMR characterization, but since
crystallization was not possible no X-ray structure determination could be made: the
configuration at C(5) remained unknown.
3.5 Separation and purification
All glycosylated compounds were − as far as possible − separated and purified by
column chromatography on silica gel. Due to the carbohydrate structure, these compounds
had to be eluted with rather polar solvents, such as AcOEt in CH2Cl2 or 5% MeOH in CH2Cl2.
With such polarities, it was very difficult not to elute impurities and the carbohydrate
together.
Furthermore, carbohydrates can be very difficult to crystallize. So it is not surprising
that we could not recrystallize the glycosylated compounds, even when amourphous solids
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were easily obtained after evaporation of the solvent. Preparative HPLC was not suitable for
our compounds, as they were not active enough in UV.
4. Deacetylation
In general, the cleavage of acetyl groups on carbohydrates is very simple. The reaction
is usually carried out under basic conditions. The most common procedure is the use of
MeONa in methanol, however any other strong base can be used. The cleavage can also be
done in aqueous solution with NaOH, KOH, or K2CO3 for instance. Another possibility is the
use of NH3 in methanol. There are many other ways to achieve this cleavage: e.g. an
enzymatic reaction with a lipase or an esterase [59, 60], or the use of Bu2SnO as a catalyst
[61] can be alternative routes. An acid catalysed deacetylation was described by Byramova et
al. [62]; this process uses HCl gas, dissolved in anhydrous methanol and selectively cleaves
acetates, whereas benzoates do not react.
4.1 Searching for the best method
The classical method to deacetylate carbohydrates is the basic reaction with NaOMe in
MeOH. This method was applied to the compound 92, and not only the deacetylation
occurred, but also the cleavage of the new glycosidic bond: only glucose and a furanone
derivative were isolated. All aqueous bases, like NaOH, K2CO3, and NaHCO3, gave the same
result (Scheme 27).
The use of nitrogenated organic bases, like triethylamine, sym.-collidine, N,N-
diphenylguanidine, dicyanodiamide, diisopropylethylamine (Hünig base) gave no
deacetylation.
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Scheme 27: results for different deacetylation methods.
The only base, which gave complete deacetylation without cleaving the glycosidic
bond was guanidine [63].
In the literature, a procedure using HCl in anhydrous methanol was published. Such a
procedure could be interesting in our case, as the glycosidic bond in our compounds proved to
be unstable under strong basic conditions. However, this deacetylation method requires the
neutralization of the acid with a strong base. Therefore, such a process is not suitable for our
compounds.
4.2 Deacetylation with guanidine
Guanidine base is prepared by running a solution of guanidine hydrochloride in MeOH
through an anionic ion exchange resin, such as Amberlite IRA-900Cl. The deacetylation is
carried out in CH2Cl2/EtOH 1/9 and is followed by TLC. The amount of guanidine used is
very critical: too much base as well as too long reaction times lead to the cleavage of the
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glycosidic bond. Therefore, guanidine is added in portions, depending on how the
deacetylation is proceeding.
In fact, the reaction conditions are not anhydrous, since the guanidine was not dried.
Moreover, each acetate requires one H2O molecule for the cleavage. Therefore deacetylation
cannot be carried out under strictly anhydrous conditions. Since in our case water is present in
a large excess and the conditions are basic, the destruction of part of the deacetylated product
cannot be avoided. A compromise between deacetylation and destruction must be found in
order to optimize the yield.
Scheme 28: Results of the deacetylations.
Deacetylation of the compounds 92 and 96 gave the respective glycosylated furanones
101 and 102 (Scheme 28). Deprotection of 92 could only be achieved with a poor yield
(10%). Deacetylation of 96 proceeded somewhat easier (30% yield) and afforded the
acetamido-glucopyranosyl furanone 102, thus only the O-acetyl groups had been removed
whereas the amide function was left intact. On the other hand, deacetylation of the
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peracetylated cellobiose derivative 97 afforded only partially deacetylated compounds, and it
was not possible to isolate the wanted product 103.
4.3 Purification
The reaction was stopped by pouring the reaction mixture directly onto a silica gel
column. Evaporation of the reaction mixture before chromatography must be avoided,
because the increasing concentration of the base would lead to cleavage of the glycosidic
bond.
The deacetylated products needed a very polar solvent for the elution from the silica
gel, such as MeOH in CH2Cl2 15%. Such a polar solvent did not enable a perfect removal of
all impurities. Also, a separation of the diastereomer mixtures 101 and 102 into the single
compounds was not possible.
Similarly to the acetylated derivatives (e.g. 96), the deacetylated compounds 101 and
102 were obtained as amorphous solids after solvent evaporation.
4.4 Discussion
The deacetylated compounds 101 and 102 could not be purified by chromatography on
aluminium oxide and on basic ion exchange resins either. These methods led to the
destruction of the products. In addition, our experiments showed that the glycosidic bond
sugar/furanone was not stable under basic conditions. This explains why the glycosylation did
not work under basic conditions, for instance with DBU or NaH. However, the compounds
are stable for more than several months when stored in an anhydrous argon atmosphere. What
can explain the instability of the glycosides 101 and 102 in the presence of aqueous bases?
When the acetylated glycoside 92 is treated with MeONa in MeOH, the 4-methyl-5-
methoxy-5H-furan-2-one (100) [64] is isolated. This means that the methoxide ion attacks the
electrophilic C(5) (Scheme 29), followed by cleavage of the glycosidic bond; an attack at the
carbonyl C(2) would lead to a methyl ester, which is not observed.
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Scheme 29: Cleavage of glycosidic bond with methoxide.
We can assume that under basic aqueous conditions, not only opening of the lactone
can occur, but also hydroxide can add to C(5) similarly to methoxide, leading to the cleavage
of the glycosidic bond sugar/furanone. This could explain the instability of 101 and 102 under
basic aqueous conditions.
Surprisingly, the deacetylation of the mixture 96 afforded the compound 102 as a
mixture of only three diastereomers. According to the NMR analyses, both furanone C(5)
epimers with an α-configuration of the sugar were obtained, but only one β-anomer. When
the deacetylation was performed separately with each of the two β-epimers 96c and 86d, only
the former gave the corresponding deacetylated carbohydrate 102c. Thus, we suppose that the
lacking isomer is 102d. However, we cannot explain this different behaviour so far.
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IV Biological tests
1. Test conditions
All biological tests were performed by the group of Prof. Spindler, University of Ulm,
Germany.
The furanone derivatives were tested with four different enzymes: Chitinase A and
Chitinase B from the bacterium Serratia marcescens and a chitinase, as well as a N-acetyl-β-
D-glucosaminidase, from the insect Chironomus tentans. The activities were measured by
fluorimetry and the substrates were methylumbelliferyl-N-acetylglucosamine (MUF-
GlcNAc), methylumbelliferyl-chitobiose (MUF-chitobiose) and methylumbelliferyl-
chitotriose (MUF-chitotriose) in a sodium citrate/phosphate buffer, at pH 5.5.
2. Results
The mentylated furanones 47a and 47b, as well as the compounds 104 and 105 were
tested for chitinase inhibition. The latter two compounds were obtained from furanone 37 by
derivatization with (+)-menthol and (+)-isomenthol, respectively (see Experimental Part).
Compound 105 is the enantiomer of 38b. Acetylated monosaccharides 92, 96a, 96b, 96c, 96d,
acetylated disaccharide 97, and deacetylated glucosamine derivative 102 were also tested
(Figure 17). The deacetylated glucose derivative 101 was not tested, since it was not possible
to purify it completely.
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Figure 17: Chitinase inhibition of furanone derivatives. Data of compound 97 (inactive) are
not shown
Only the compounds 47a and 47b showed a significant inhibition effect. This activity
was strong with chitinase A from Serratia marcescens, and weak but still significant with the
chitinase from Chironomus tentans. It can be concluded that 47a and 47b are specific
inhibitors to chitinase A from Serratia marcescens. The derivatives 104 and 105 were not
active.
The glycosylated furanones 92, 96a, 96b, 96c and 96d did not have any significant
activity. Only the deacetylated compound 102 showed a very slight inhibition, but this was
not significant enough to be considered.
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3. Discussion
Only compounds 47a and 47b were active. Other menthylated furanones were also
active [37]. The derivatives without side chain at C(3) (38b, 104, 105) were not inhibitors: the
presence of a menthyl group, or a similar derivative like isomenthyl, on the furanone is not
sufficient to give an inhibiton effect.
The allosamizoline part of allosamidin can be easily protonated during the inhibition
process [65] (Figure 18). With our furanones derivatives, such as compound 47a, containing a
secondary alcohol in the side chain, this is also possible. However, protonation would be
much weaker than in allosamidin. Furanones 38b, 104 and 105 contain no side chain, which
means that protonation is not possible (Figure 19). This might explain why these compounds
were not active.
Figure 18: “Proposed catalytic mechanism. Asp-140, Asp-142 and Glu-144, conserved in
most family 18 chitinases, are shown during separate stages of catalysis. (A) Resting enzyme.
Asp-142 is too far away to interact with Glu-144. (B) Binding of substrate causes distorsion
of the pyranose ring to a boat or skewed boat conformation and rotation of Asp-142 toward
Glu-144, enabling hydrogen bond interactions between the hydrogen of acetamido group,
Asp-142, and Glu-144. (C) Hydrolysis of the oxazolinium ion intermediate leads to
protonation of Glu-144 and rotation of Asp-142 to ist original position where it shares a
proton with Asp-140.” [65]
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Figure 19: Hypothetical reactivity of furanones in the active site of chitinases.
The acetylated compounds 92, 96a, 96b, 96c, 96d and 97 were not active. We had
previously pointed out that the substrate chitin was held in the active site of the chitinase
through hydrogen bonds. Acetylated sugar derivatives cannot have these interactions in the
same way. This could explain why our acetylated furanone glycosides were found to be
inactive. In this context it was interesting to note that the deacetylated compound 102 had a
very slight inhibitory activity.
V Conclusion and perspective
The synthesis of glycosylated furanones could be achieved. However, the new
glycosidic bond proved to be unstable under basic aqueous conditions. This led to low yields
during the synthesis, particularly during the final deacetylation, during which it remained
impossible to get a full deacetylation without degradation of a large part of the product.
Therefore, the use of an other protecting group was taken into account. The protection
of glucose with phenoxyacetic acid was tried, but the preparation of the carbohydrate before
the glycosylation was much less convenient than with acetic acid, and it was much more
expensive. This synthetic route was not investigated further.
The biological tests also showed that the addition of a cyclohexane derivative or a
sugar on the furanone was not sufficient to have a significant inhibition. The presence of a
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side chain with a secondary alcohol is also required. Therefore, if an aldehyde is condensed
with the glycosylated furanones, in the same way as the menthylated furanones, the
bioactivity should increase. However, this condensation occurs under basic conditions, and it
was seen that the glycosidic bond was not stable under basic conditions. The only way to get
glycosylated furanones with a side-chain is to introduce the aldehyde first, and then to
glycosylate the substituted furanone.
The instability of the linkage between the furanone and the sugar remains the strongest
problem of these compounds: this glycosidic bond is very sensitive to hydrolysis. Therefore,
even if the compound 102 would have been active in vitro, it might not be possible to use it in
vivo. The synthesis of C-glycosides like 106 should be considered. In fact, C-glycosides are
not sensitive to hydrolysis [66], and their structure analogy with O-glycosides can confer
them interesting bioactivities. E.g. some C-disaccharides were found to be glycohydrolase
inhibitors [67].
O
NHAc
OH
HO
HO
O
O
106
OH
74
B. Experimental Part
General remarks
Chemicals were purchased from Fluka AG, Merck GmbH, Acros Organics, and Sigma-
Aldrich Chemical Company, Inc.
Absolute solvents were bought in puriss quality. THF was distilled over sodium and
benzophenone, under argon. Absolute methanol and dichloromethane were stored under argon
over 4 Å molecular sieves.
Solvent evaporations were performed on a Büchi Rotavapor R-114 with a water bath Büchi
B-480 at 40 °C; the final pressure was 15 mbar; all products were dried overnight under high
vacuum at 0.06-0.1 mbar.
Flash chromatographies were eluted with distilled solvents from a technical quality and with
air pressure at the top of the column. Silica gel was purchased from Macherey-Nagel, 60M
0.040-0.063 mm. Solvent ratios are given in volume percentage.
Meting points were measured on a Büchi 535.
Optical rotations were measured on a Perkin Elmer polarimeter 341 in a 10 cm cell.
Infrared spectra were measured on a spectrometer Perkin Elmer 1600 Series FT-IR, using
potassium bromide pellets or a substance film between sodium chloride plates. Resonance
frequencies are given in cm−1.
NMR spectra were measured on a Bruker VRX 500 (1H-NMR 500 MHz; 13C-NMR
125 MHz) with the help of Dr. K. Kulicke. The chemical shifts δ are given in ppm. Reference
for proton is TMS at 0.00 ppm. Reference for carbon is CDCl3 at 77.0 ppm. Assignments
were made from APT, COSY, HMQC, HMBC. CDCl3 with 0.05% TMS was stored over a
silver foil. CD3OD was purchased in 1 g glass ampoules. DMSO-d6 containing 0.05 % TMS
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was stored in a dessicator. All solvents were purchased from Cambridge Isotope
Laboratories, Inc.
Mass spectra were measured by Dr. H. Nadig on the spectrometers VG 70SE, Finnigan
MAT95Q (EI, 70 eV), and Finnigan MAT312 [FAB, matrix: 3-nitrobenzyl alcohol (NBA)].
We report m/z values with their respective intensities in parentheses
Elemental analysis were performed by W. Kirsch from the Microanalytical Laboratory.
X-ray structures were measured by Dr. M. Neuburger, from the Institute of Inorganic
Chemistry, University of Basel.
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Part One
Furanones with an aliphatic side-chain
I Synthesis of both enantiomers of 3-[1-hydroxy-2,2-dimethylpropyl]-4-
methyl-5H-furan-2-one 56a and 56b
1. Synthesis of the mixture of (5R)-3-[(1S)-hydroxy-2,2-dimethylpropyl]-5-{[(1R,2S,5R)-2-
isopropyl-5-methylcyclohexyl]oxy}-4-methyl-5H-furan-2-one (47a) and (5R)-3-[(1R)-
hydroxy-2,2-dimethylpropyl]-5-{[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]oxy}-4-
methyl-5H-furan-2-one (47b).
A solution of freshly distilled diisopropylamine (11 ml, 77 mmol) in freshly distilled
THF (450 ml) was cooled to 0°C under argon. n-BuLi in hexane (55 ml, 79 mmol) was added
dropwise over 30 min and the resulting solution was stirred for 30 min at 0°C. Then, the
mixture was cooled to −100°C (ether in hexane 20%, liquid N2) and a solution of (5R)-5-
{[(1R, 2S, 5R)-2-isopropyl-5-methylcyclohexyl]oxy}-4-methyl-5H-furan-2-one [14] (38b,
15 g, 59 mmol) in THF (35 ml) was added dropwise during 30 min and the resulting solution
was stirred for 30 min at −100°C. Pivalaldehyde (8.5 ml, 77 mmol) was added dropwise
during 30 min and the mixture was stirred for further 30 min at −100°C. After a slow warm-
up to −20°C, the reaction was quenched with saturated NH4Cl solution (400 ml) and the
mixture was extracted with CH2Cl2 (3 × 300 ml), washed with saturated NaHCO3 solution
(3 × 300 ml) and saturated NaCl solution (3 × 300 ml), dried (MgSO4) and evaporated. The
residue was chromatographed (SiO2, CH2Cl2) to afford 47 as a mixture of 2 diastereomers. A
second chromatography (SiO2, EtOAc in hexane 10%) enabled the separation of 47a and 47b.
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OH
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CHO
C20H34O4
Mol. Wt.: 338.48
43
77
1.1 Data of (5R)-3-[(1S)-hydroxy-2,2-dimethylpropyl]-5-{[(1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl]oxy-4-methyl-5H-furan-2-one (47a)
Yield: 3.85g, 19%
Colorless needles, Mp 112.7-113.6°C.
[α]D20 = −153.5 (c = 1.00, CHCl3 stab. 1% EtOH).
IR (KBr): 3497, 2956, 1733, 1681, 1449, 1363, 1326, 1278, 1240, 1182, 1098, 1049, 1011,
937.
1H-NMR (500 MHz, CDCl3): δ = 5.75 (s, 1 H, H-C(5)); 4.18 (d, J = 8.7 Hz, 1 H, H-C(1’));
3.62 (td, J = 10.5, 4 Hz, 1 H, H-C(1’’)); 3.36 (d, J = 8.6 Hz, 1 H, HO-C(1’)); 2.15-2.06 (m,
2 H, Heq-C(6’’) and H-C(8’’)); 1.99 (s, 3 H, H3C-C(4)); 1.72-1.63 (m, 2 H, Heq-C(4’’) and
Heq-C(3’’)); 1.48-1.35 (m, 1 H, H-C(5’’)); 1.30-1.21 (m, 1 H, H-C(2’’)); 1.12-0.85 (m, 3 H,
Hax-C(6’’), Hax-C(4’’) and Hax-C(3’’));0.96 (d, J = 7 Hz, 3 H, H3C(7’’)); 0.95 (s, 9 H,
(H3C)3-C(2’)); 0.88 (d, J = 7 Hz, 3 H, H3C(9’’)); 0.80 (d, J = 7 Hz, 3 H, H3C(10’’)).
13C-NMR (125 MHz, CDCl3): δ = 172.6 (C(2)); 158.0 (C(4)); 129.3 (C(3)); 100.9 (C(5));
79.8 (C(1’’)); 75.7 C(1’)); 48.2 (C(2’’)); 40.8 (C(6’’)); 38.2 (C(2’)); 34.6 (C(4’’)); 31.9
(C(5’’)); 26.4 ((CH3)3-C(2’)); 25.7 (C(8’’)); 23.6 (C(3’’)); 22.6 (C(7’’)); 21.2 (C(9’’)); 16.2
(C(10’’)); 13.0 (CH3-C(4)).
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EI-MS (70 eV, 200°C): m/z (%) = 282 (16), 281 (13), 166 (16), 144 (82), 143 (31), 139 (72),
127 (47), 126 (100), 97 (18), 95 (14), 83 (85), 81 (21), 69 (36), 57 (65), 55 (38), 43 (21), 41
(36).
FAB-MS (NBA): m/z (%) = 340 (21), 339 ([M + H]+, 100), 201 (26), 183 (98), 165 (24), 139
(28), 127 (37), 125 (11), 97 (15), 83 (85), 81 (19),69 (32), 57 (49), 55 (32), 43 (14), 41 (20).
Anal. calc. for C20H34O4 (338.48): C, 70.97; H, 10.12; O, 18.91. Found: C, 71.01; H, 10.04;
O 18.77.
1.2 Data of (5R)-3-[(1R)-hydroxy-2,2-dimethylpropyl]-5-{[(1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl]oxy-4-methyl-5H-furan-2-one (47b)
Yield: 3.50g, 17%.
Colorless needles, Mp 85.5-86.8°C.
[α]D20 = −108.5 (c = 1.00, MeOH).
IR (KBr): 3442, 2954, 1745, 1678, 1459, 1368, 1338, 1297, 1241, 1178, 1106, 1003, 952.
1H-NMR (500 MHz, CDCl3): δ = 5.68 (s, 1 H, H-C(5)); 4.17 (d, J = 9.5 Hz, 1 H, H-C(1’));
3.64 (td, J = 10.5, 4 Hz, 1 H, H-C(1’’)); 3.53 (d, J = 9.5 Hz, 1 H, HO-C(1’)); 2.15-2.03 (m,
2 H, Heq-C(6’’) and H-C(8’’)); 1.97 (s, 3 H, H3C-C(4)); 1.72-1.63 (m, 2 H, Heq-C(4’’) and
Heq-C(3’’)); 1.47-1.37 (m, 1 H, H-C(5’’)); 1.29-1.23 (m, 1 H, H-C(2’’)); 1.09-0.85 (m, 3 H,
Hax-C(6’’), Hax-C(4’’) and Hax-C(3’’));0.96 (d, J = 7 Hz, 3 H, H3C(7’’)); 0.95 (s, 9 H,
(H3C)3-C(2’)); 0.88 (d, J = 7 Hz, 3 H, H3C(9’’)); 0.81 (d, J = 7 Hz, 3 H, H3C(10’’)).
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13C-NMR (125 MHz, CDCl3): δ = 172.2 (C(2)); 157.2 (C(4)); 128.7 (C(3)); 100.6 (C(5));
79.4 (C(1’’)); 75.4 C(1’)); 47.8 (C(2’’)); 40.4 (C(6’’)); 37.7 (C(2’)); 34.4 (C(4’’)); 31.5
(C(5’’)); 26.0 ((CH3)3-C(2’)); 25.8 (C(8’’)); 23.7 (C(3’’)); 22.2 (C(7’’)); 20.7 (C(9’’)); 16.2
(C(10’’)); 12.7 (CH3-C(4)).
EI-MS (70 eV, 200°C): m/z (%) = 282 (17), 281 (13), 166 (13), 144 (89), 143 (31), 139 (70),
127 (45), 126 (100), 97 (19), 95 (17), 83 (92), 81 (23), 69 (40), 57 (69), 55 (42), 43 (22), 41
(40).
FAB-MS (NBA): m/z (%) = 340 (22), 339 ([M + H]+, 96), 201 (28),184 (12), 183 (100), 165
(23), 139 (29), 127 (35), 125 (10), 97 (14), 83 (88), 81 (20),69 (30), 57 (50), 55 (35), 43 (16),
41 (22).
Anal. calc. for C20H34O4 (338.48): C, 70.97; H, 10.12; O, 18.91. Found: C, 70.93; H, 10.06;
O 18.78.
2. Synthesis of 5-hydroxy-3-[(1S)-1-hydroxy-2,2-dimethylpropyl]-4-methyl-5H-furan-2-one
(52a)
(5R)-3-[(1S)-1-hydroxy-2,2-dimethylpropyl]-5-{[(1R, 2S, 5R)-2-isopropyl-5-
methylcyclohexyl]oxy}-4-methyl-5H-furan-2-one (47a, 1.0 g, 3.0 mmol) was dissolved in
absolute CH2Cl2 (50 ml). The solution was cooled to −78°C and BBr3 (0.86 ml, 8.9 mmol)
was added. After a reaction time of 4 hours at −78°C, additional BBr3 (0.86 ml, 8.9 mmol)
was added at −78°C, the resulting mixture was allowed to warm up to −20°C and saturated
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NaHCO3 solution (25 ml) was added. After warming up to r.t., the mixture was extracted
EtOAc (3 × 100 ml). The combined organic phases were dried (MgSO4) and the solvent was
evaporated. The residue was chromatographed (SiO2, 33% EtOAc in hexane) to give 52a.
Yield: 482 mg, 81%.
colorless cubes (EtOH), Mp 162.3-162.7°C.
[α]D20 = −41.5 (c = 1.00, MeOH).
IR (KBr): 3473, 3264, 2959, 2868, 1729, 1675, 1459, 1384, 1363, 1341, 1297, 1271, 1177,
1155, 1098, 1030, 1006, 950.
1H-NMR (500 MHz, d6-DMSO): δ = 7.75 (d, J = 7.5 Hz, 1 H, HO-C(5A)); 7.66 (d,
J = 8.5 Hz, 1 H, HO-C(5B)); 5.93 (d, J = 7.5 Hz, 1 H, H-C(5A or B)); 5.80 (d, J = 8.5 Hz, 1 H,
H-C(5B or A)); 5.12 (d, J = 4.9 Hz, 2×1 H, HO-C(1’A and B)); 4.14 (d, J = 4.7 Hz, 1 H,
H-C(1’A or B)); 4.11 (d, J = 4.5 Hz, 1 H, H-C(1’2 or 1)); 2.09 (s, 2×3 H, H3C-C(41 and 2)); 0.90 (s,
9 H, (H3C)3-C(2’1 or 2)); 0.89 (s, 9 H, (H3C)3-C(2’2 or 1)).
13C-NMR (125 MHz, d6-DMSO): δ = 172,72 and 172,36 (C(2)); 161.08 and 160.44 (C(4));
130.2 (C(3)); 98.90 and 98.84 (C(5)); 73.82 and 73.73 (C(1’)); 38.12 and 37.97 (C(2’)); 26.9
((CH3)3-C(2’)); 13.88 and 13.67 (CH3-C(4)).
EI-MS (70 eV, 300°C): m/z (%) = 167 (32), 149 (43), 144 (11), 127 (10), 126 (100), 98 (17),
97 (15), 70 (12), 69 (26), 57 (85), 55 (11), 44 (12), 43 (19), 41 (68), 39 (34).
FAB-MS (NBA): m/z (%) = 339 (9), 202 (10), 201 ([M + H]+, 100), 183 (64), 165 (42), 139
(11), 137 (34), 136 (48), 127 (16), 120 (17), 107 (16), 91 (16), 90 (22), 83 (34), 81 (10), 77
(10), 69 (34), 67 (12), 57 (79), 55 (46), 53 (11), 43 (46), 41 (35).
Anal. calc. for C10H16O4 (200.23): C, 59.98; H, 8.05; O, 31.96. Found: C, 60.08; H, 7.90;
O, 32.04.
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3. Synthesis of 5-hydroxy-3-[(1R)-1-hydroxy-2,2-dimethylpropyl]-4-methyl-5H-furan-2-one
(52b)
(5R)-3-[(1R)-1-hydroxy-2,2-dimethylpropyl]-5-{[(1R, 2S, 5R)-2-isopropyl-5-
methylcyclohexyl]oxy}-4-methyl-5H-furan-2-one (47b, 1.0 g, 3.0 mmol) was dissolved in
absolute CH2Cl2 (50 ml). The solution was cooled to −78°C and BBr3 (0.86 ml, 8.9 mmol)
was added. After a reaction time of 4 hours at −78°C, additional BBr3 (0.86 ml, 8.9 mmol)
was added at −78°C, the resulting mixture was allowed to warm up to −20°C and saturated
NaHCO3 solution (25 ml) was added. After warming up to r.t., the mixture was extracted
EtOAc (3 × 100 ml). The combined organic phases were dried (MgSO4) and the solvent was
evaporated. The residue was chromatographed (SiO2, 33% EtOAc in hexane) to give 52b.
Yield: 330 mg, 66%.
colorless cubes (EtOH), Mp 162.0-162.7°C.
[α]D20 = +39.0 (c = 1.00, MeOH).
IR (KBr): 3473, 3342, 2959, 2868, 1729, 1714, 1675, 1460, 1384, 1363, 1340, 1278, 1177,
1155, 1098, 1030, 1006, 950
1H-NMR (500 MHz, d6-DMSO): δ = 7.71 (d, J = 7.5 Hz, 1 H, HO-C(51)); 7.62 (d, J = 8.5 Hz,
1 H, HO-C(52)); 5.90 (dd, J = 7.5, 0.6 Hz, 1 H, H-C(51 or 2)); 5.76 (dd, J = 8.5, 0.2 Hz, 1 H,
H-C(52 or 1)); 5.08 (d, J = 5 Hz, 2×1 H, HO-C(1’1 and 2)); 4.11 (d, J = 4.5 Hz, 1 H, H-C(1’1 or 2));
4.07 (d, J = 4.5 Hz, 1 H, H-C(1’2 or 1)); 2.06 (s, 3 H, H3C-C(41 or 2)); 2.05 (s, 3 H,
H3C-C(42 or 1)); 0.86 (s, 9 H, (H3C)3-C(2’1 or 2)); 0.85 (s, 9 H, (H3C)3-C(2’2 or 1)).
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13C-NMR (125 MHz, d6-DMSO): δ = 172,71 and 172,36 (C(2)); 161.07 and 160.44 (C(4));
130.18 (C(3)); 98.90 and 98.84 (C(5)); 73.81 and 73.73 (C(1’)); 38.12 and 37.97 (C(2’)); 26.9
((CH3)3-C(2’)); 13.89 and 13.67 (CH3-C(4)).
EI-MS (70 eV, 300°C): m/z (%) = 144 (14), 126 (100), 97 (11), 69 (16), 57 (50), 41 (29), 39
(12).
FAB-MS (NBA): m/z (%) = 409 (18), 339 (9), 202 (11), 201 ([M + H]+, 100), 183 (74), 165
(49), 139 (15), 137 (33), 136 (73), 127 (13), 125 (13), 121 (11), 120 (25), 107 (12), 97 (13),
91 (12), 90 (18), 83 (48), 81 (15), 69 (39), 57 (77), 55 (37), 43 (36), 41 (31).
Anal. calc. for C10H16O4 (200.23): C, 59.98; H, 8.05; O, 31.96. Found: C, 60.20; H, 7.89;
O, 31.71.
4. Synthesis of 3-[(1S)-1-hydroxy-2,2-dimethylpropyl]-4-methyl-5H-furan-2-one (56a)
A solution of 5-hydroxy-3-[(1S)-1-hydroxy-2,2-dimethylpropyl]-4-methyl-5H-furan-
2-one (52a, 200 mg, 1.0 mmol) in absolute MeOH (5 ml) was cooled at 0°C. NaBH4 (200 mg,
5.3 mmol) was added in portions within 10 min and the solution was stirred 45 min at r.t.
Then the reaction mixture was quenched with H2O (5 ml) and extracted with CH2Cl2
(3 × 5 ml). The combined organic layers were dried (MgSO4), evaporated and the residue was
chromatographed (SiO2, EtOAc in hexane 33%) to give 56a.
Yield: 134 mg, 73%.
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colorless solid, Mp 77-78°C.
[α]D20 = −28.4 (c = 1.00, CH2Cl2).
IR (KBr): 3454, 2975, 2861, 1734, 1662, 1483, 1469, 1440, 1389, 1363, 1350, 1293, 1243,
1219, 1179, 1121, 1088, 1039, 1016, 992, 943, 896.
1H-NMR (500 MHz, CDCl3): δ = 4.73 (d, J = 17.5 Hz, 1 H, HA-C(5)); 4.65 (d, J = 17.5 Hz,
1 H, HB-C(5)); 4.20 (d, J = 9.5 Hz, 1 H, H-C(1‘)); 3.66 (d, J = 9.5 Hz, 1 H, HO-C(1’)); 2.08
(s, 3 H, H3C-C(4)); 0.96 (s, 9 H, (CH3)3-C(2’)).
13C-NMR (125 MHz, CDCl3): δ = 174.8 (C(2)); 159.3 (C(4)); 126.3 (C3)); 75.2 (C(1’)); 72.8
(C(5)); 37.8 (C(2’)); 25.9 ((CH3)3-C(2’)); 13.3 (CH3-C(4));
EI-MS (70 eV, 100°C): m/z (%) = 151 (13), 128 (80), 127 (64), 110 (100), 99 (12), 82 (65),
57 (49), 53 (13), 43 (18), 41 (35), 39 (19).
FAB-MS (NBA): m/z (%) = 186 (10), 185 ([M + H]+, 100), 167 (82), 137 (16), 136 (8), 127
(16), 77 (11), 57 (24), 41 (17), 39 (16).
Anal. calc. for C10H16O3 (184.23): C, 65.19; H, 8.75; O, 26.05. Found: C, 64.97; H, 8.78;
O, 26.12.
5. Synthesis of 3-[(1R)-1-hydroxy-2,2-dimethylpropyl]-4-methyl-5H-furan-2-one (56b)
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A solution of 5-hydroxy-3-[(1R)-1-hydroxy-2,2-dimethylpropyl]-4-methyl-5H-furan-
2-one (52b, 200 mg, 1.0 mmol) in absolute MeOH (5 ml) was cooled at 0°C. NaBH4 (200 mg,
5.3 mmol) was added in portions within 10 min and the solution was stirred 45 min at r.t.
Then the reaction mixture was quenched with H2O (5 ml) and extracted with CH2Cl2
(3 × 5 ml). The combined organic layers were dried (MgSO4), evaporated and the residue was
chromatographed (SiO2, EtOAc in hexane 33%) to give 56b.
Yield: 118 mg, 64%.
colorless solid, Mp 77-78°C.
[α]D20 = +27.0 (c = 1.00, CH2Cl2).
IR (KBr): 3454, 2975, 2861, 1734, 1662, 1483, 1469, 1440, 1382, 1363, 1350, 1293, 1243,
1219, 1179, 1121, 1088, 1039, 1016, 992, 943, 896.
1H-NMR (500 MHz, CDCl3): δ = 4.73 (d, J = 17.5 Hz, 1 H, HA-C(5)); 4.65 (d, J = 17.5 Hz,
1 H, HB-C(5)); 4.20 (d, J = 9.5 Hz, 1 H, H-C(1‘)); 3.66 (d, J = 9.5 Hz, 1 H, HO-C(1’)); 2.08
(s, 3 H, H3C-C(4)); 0.96 (s, 9 H, (CH3)3-C(2’)).
13C-NMR (125 MHz, CDCl3): δ = 174.8 (C(2)); 159.3 (C(4)); 126.3 (C3)); 75.2 (C(1’)); 72.8
(C(5)); 37.8 (C(2’)); 25.9 ((CH3)3-C(2’)); 13.3 (CH3-C(4));
EI-MS (70 eV, 100°C): m/z (%) = 151 (13), 128 (80), 127 (64),123 (11), 110 (100), 99 (12),
82 (65), 57 (49), 53 (13), 43 (18), 41 (35), 39 (19).
FAB-MS (NBA): m/z (%) = 186 (10), 185 ([M + H]+, 100), 167 (82), 137 (14), 136 (10), 127
(14), 77 (14), 57 (12), 41 (12), 39 (13).
Anal. calc. for C10H16O3 (184.23): C, 65.19; H, 8.75; O, 26.05. Found: C, 65.24; H, 8.75; O,
26.34.
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II Synthesis of 4-methyl-3-pentyl-5H-furan-2-one 52 (64, MP133)
1. Synthesis of 3-(1-hydroxypentyl)-5-{[(1R,2S,5R)-2-isopropyl-5-methylcycloheyl]-oxy}-4-
methyl-5H-furan-2-one (60)
A solution of freshly distilled diisopropylamine (11 ml, 77 mmol) in freshly distilled
THF (500 ml) was cooled to 0°C under argon. n-BuLi in hexane (53 ml, 80 mmol) was added
dropwise over 30 min and the resulting solution was stirred for 30 min at 0°C. Then, the
mixture was cooled to −100°C (hexane-ether 80:20, liquid N2) and a solution of 5-{[(1R, 2S,
5R)-2-isopropyl-5-methylcyclohexyl]oxy}-4-methyl-5H-furan-2-one [14] (38a-b, 15 g,
59 mmol) in THF (30 ml) was added dropwise during 30 min and the resulting solution was
stirred for 30 min at −100°C. Pentanal (59, 8 ml, 75 mmol) was added dropwise during
30 min and the mixture was stirred for further 30 min at −100°C. After a slow warm-up to
−20°C, the reaction was quenched with saturated NH4Cl solution (300 ml) and the mixture
was extracted with CH2Cl2 (3 × 300 ml), washed with saturated NaHCO3 solution
(3 × 300 ml) and saturated NaCl solution (3 × 300 ml), dried (MgSO4) and evaporated. The
residue was chromatographed (SiO2, EtOAc in CH2Cl2 0 to 10%) to afford 60 as a mixture of
4 diastereomers.
Light yellow oil, yield: 9.0g, 45%.
1H-NMR (500 MHz, CDCl3): δ = 5.72, 5.70, 5.61, 5.60 (4 s, 1 H, H-C(5)); 4.49-4.43 (m, 1 H,
H-C(1’)); 3.66-3.47 (2 m,1 H, H-C(1’’)); 2.89 (d, J = 9.2 Hz), 2.88 (d, J = 9.0 Hz), 2.82 (d,
J = 8.4 Hz), 2.75 (d, J = 8.4 Hz) (1 H, HO-C(1’)); 2.33-2.07 (3 m, 2 H, H-C(8’’) and
Heq-C(6’’)); 2.04, 2.02, 1.99, 1.98 (4 s, 3 H, H3C-C(4)); 1.88-1.78 (m, 1 H, HA-C(2’)); 1.71-
1.62 (m, 3 H, Heq-C(4’’), Heq-C(3’’) and HB-C(2’)); 1.45-1.22 (m, 6 H, H2C(3’), H2C(4’),
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H-C(2’’) and H-C(5’’)); 1.11-0.85 (m, 12 H, Hax-C(6’’), Hax-C(4’’), Hax-C(3’’), H3C(5’),
H3C(7’’), and H3C(9’’)), 0.83-0.77 (m, 3 H, H3C(10’’)).
13C-NMR (125 MHz, CDCl3): δ = 171.47, 171.42, 171.31, 171.28 (C(2)); 155.39, 155.35,
155.23, 155.06 (C(4)); 130.81, 130.73, 130.70, 130.58 (C(3)); 104.73, 104.50, 100.85, 100.69
(C(5)); 83.59, 83.43, 79.50, 79.45 (C(1’’)); 66.96, 66.90, 66.87, 66.83 (C(1’)); 48.12, 48.09,
47.70, 47.66 (C(2’’)), 42.33, 40.42, 40.38 (C(6’’)); 36.38, 36.34, 36.19, 36.13 (C(2’)); 34.18,
34.05 (C(4’’)); 31.63, 31.42 (C(5’’)); 27.63, 27.56 (C(3’)); 25.41, 25.39, 25.32, 25.13
(C(8’’)); 23.19, 23.04, 22.84, 22.82 (C(3’’)); 22.40, 22.38, 22.22, 22,21, 22.09 (C(4’) and
C(7’’)); 20.93, 20.91, 20.84, 20.78 (C(9’’)); 15.84, 15.70 (C(10’’)); 13.96, 13.95 (C(5’)),
11.62, 11.48 (CH3-C(4)).
EI-MS (70 eV, 250 °C): m/z (%) = 281 (29), 183 (28), 182 (19), 167 (13), 166 (79), 155 (44),
143 (64), 140 (15), 139 (100), 138 (21), 137 (24), 127 (12), 126 (27), 123 (11), 111 (31), 110
(35), 109 (10), 97 (24), 95 (33), 85 (49), 83 (96), 82 (10), 81 (53), 71 (14), 69 (63), 67 (19),
57 (53), 55 (64), 43 (39), 41 (59), 39 (12).
FAB-MS (NBA): m/z (%) = 340 (14), 339 ([M + H]+, 64), 201 (15), 184 (11), 183 (87), 97
(15), 85 (12), 83 (100), 81 (20), 77 (13), 69 (39), 67 (11), 57 (37), 55 (39), 43 (17), 41 (30),
39 (19).
Anal. calc. for C20H34O4 (338.48): C, 70.97; H, 10.12. Found: C, 70.96; H, 10.21.
2. Synthesis of 5-hydroxy-3-(1-hydroxypentyl)-4-methyl-5H-furan-2-one (61)
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3(1-Hydroxypentyl)-5-{[(1R, 2S, 5R)-2-isopropyl-5-methylcyclohexyl]oxy}-4-methyl-
5H-furan-2-one (60, 7.3 g, 21 mmol) was dissolved in absolute CH2Cl2 (300 ml). The solution
was cooled to −78°C and BBr3 (6 ml, 62 mmol) was added. After a reaction time of 4 hours at
−78°C, additional BBr3 (6 ml, 62 mmol) was added at −78°C, the resulting mixture was
allowed to warm up to −20°C and saturated NaHCO3 solution (800 ml) was added. After
warming up to r.t., the mixture was extracted EtOAc (3 × 700 ml). The combined organic
phases were dried (MgSO4) and the solvent was evaporated. The residue was
chromatographed (SiO2, 10 to 50% EtOAc in hexane) to give 61 as a mixture of two pairs of
enantiomers.
Yield: 2.6g (60%).
1H-NMR (500 MHz, CDCl3): δ = 5.97 ( br s, 1 H, HO-C(5)); 5.88 and 5.85 (2 s, 1 H,
H-C(5)); 4.50-4.45 (m, 1 H, H-C(1’)); 3.43 (br s, 1 H, HO-C(1’)); 2.08 and 2.06 (2 s, 3 H,
H3C-C(4)); 1.87-1.63 (2 m, 2 H, H2C(2’)); 1.41-1.19 (m, 2 H, H2C(3’) and H2C(4’)); 0.90 (t,
3 H, J = 7 Hz, H3C(5’)).
13C-NMR (125 MHz,CDCl3): δ = 172.2 and 171.8 (C(2)); 158.3 and 158.2 (C(4)); 130.2 and
129.8 (C(3)); 98.9 and 98.8 (C(5)); 66.6 and 66.4 (C(1’)); 35.7 and 35.2 (C(2’)); 27.6 and
27.5 (C(3’)); 22.4 and 22.3 (C(4’)); 13.9 (C(5’)); 11.6 and 11.4 (CH3-C(4)).
EI-MS (70 eV, 250 °C): m/z (%) = 182 (8) 144 (12), 143 (100), 139 (28),127 (13), 126 (38),
125 (66), 115 (19), 98 (16), 97 (72), 85 (17), 71 (11), 69 (45), 67 (11), 57 (27), 55 (11), 43
(20), 41 (55), 39 (31).
FAB-MS (NBA): m/z (%) = 202 (11), 201 ([M + H]+, 100), 183 (81), 165 (16), 137 (23), 77
(11), 41 (14), 39 (13).
Anal. calc. for C10H16O4 (200.23): C, 59.98; H, 8.05. Found: C, 60.05; H, 8.14.
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3. Synthesis of 3-(1-hydroxypentyl)-4-methyl-5H-furan-2-one (62)
A solution of 5-hydroxy-3(1-hydroxypentyl)-4-methyl-5H-furan-2-one (61, 2.8 g,
14 mmol) in absolute MeOH (150 ml) was cooled at 0°C. NaBH4 (2.8g, 74 mmol) was added
in portions within 10 min and the solution was stirred overnight at room temperature. Then
the reaction mixture was quenched with H2O (150 ml) and extracted with CH2Cl2
(3 × 150 ml). The combined organic layers were dried (MgSO4), and evaporated to give 62
without further purification.
Yield: 1.9g, 74%.
1H-NMR (500 MHz, CDCl3): δ = 4.66 (s, 2 H, H2C(5)); 4.05 (t, 1 H, J = 7 Hz, H-C(1’)); 3.23
(br s, 1 H, HO-C(1’)); 2.10 ( s, 3 H, H3C-C(4)); 1.87-1.64 (m, 2 H, H2C(2’)); 1.43-1.22 (m,
4 H, H2C(3’) and H2C(4’)); 0.90 ( t, 3 H, J = 7 Hz, H3C(5’)).
13C-NMR (125 MHz,CDCl3): δ = 174.0 (C(2)); 157.8 (C(4)); 128.0 (C(3)); 72.6 (C(5)); 66.6
(C(1’)); 35.91 (C(2’)); 27.5 (C(3’)); 22.3 (C(4’)); 13.8 (C(5’)); 12.1 (CH3-C(4)).
EI-MS (70 eV, 150 °C): m/z (%) =127 (100), 99 (22), 82 (5), 71 (5), 53 (7), 43 (10), 41 (10).
FAB-MS (NBA): m/z (%) = 186 (8), 185 ([M + H]+, 81), 167 (100), 77 (11), 51 (11), 41 (14),
39 (16).
Anal. calc. for C10H16O3 (184.24): C, 65.19; H, 8.75; O, 26.05. Found: C, 64.99; H, 8.63;
O, 26.32.
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4. Synthesis of 4-methyl-3-pentyl-5H-furan-2-one (64) (MP133)
3-(1-Hydroxypentyl)-4-methyl-5H-furan-2-one (62, 708 mg, 3.8 mmol) was added to
a solution of tosyl chloride ( 817 mg, 4.3 mmol) in pyridine (4 ml) at 0°C. The reaction
mixture was stirred overnight at 4°C. After dilution with MeOH (20 ml), NaBH4 (700 mg,
19 mmol) was added and the reaction mixture was stirred for 24 hours at room temperature,
after which it was poured into aqueous 1 M HCl at 0°C. The mixture was extracted with
CH2Cl2 (3 × 50 ml), and the combined organic layers were washed with saturated NaHCO3
(3 × 50 ml) and saturated NaCl solution (3 × 50 ml), then dried (MgSO4) and evaporated
under reduced pressure. The residue was chromatographed (SiO2, 5% to 30% EtOAc in
hexane) to give 64.
Yield: 280 mg, 43%.
Colorless oil.
1H-NMR (500 MHz, CDCl3): δ = 4.62 (q, 2 H, J = 1 Hz, H2C(5)); 2.25 (t, 2 H, J = 7.5 Hz,
H2C(1’)); 2.03 ( s, 3 H, H3C-C(4)); 1.49 (quint, 2 H, J = 8 Hz, H2C(2’)); 1.36-1.25 (m, 4 H,
H2C(3’) and H2C(4’)); 0.89 (t, 3 H, J = 7 Hz, H3C(5’)).
13C-NMR (125 MHz,CDCl3): δ = 175.0 (C(2)); 156.4 (C(4)); 127.2 (C(3)); 72.3 (C(5)); 31.4
(C(3’)); 27.5 (C(2’)); 23.2 (C(1’)); 22.3 (C(4’)); 13.9 (C(5’)); 12.1 (CH3-C(4)).
EI-MS (70 eV, 100 °C): m/z = 168 (10), 153 (19), 139 (19), 113 (12), 112 (100), 111 (11), 93
(10), 69 (12), 67 (11), 55 (24), 43 (15), 41 (24), 39 (12).
FAB-MS (NBA): m/z = 170 (8), 169 ([M + H]+, 100), 167 (9), 57 (6).
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Anal. calc. for C10H16O2 (168.23): C, 71.39; H, 9.59; O, 19.02. Found: C, 71.09; H, 9.77;
O, 19.14.
III Synthesis of 3-[1-hydroxyheptyl]-4-methyl-5H-furan-2-one (57)
1. Synthesis of (5R)-3-(1-hydroxyheptyl)-5-{[(1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl]oxy}-4-methyl-5H-furan-2-one (50)
A solution of freshly distilled diisopropylamine (3.7 ml, 26 mmol) in freshly distilled
THF (250 ml) was cooled to 0°C under argon. n-BuLi in hexane (16 ml, 26 mmol) was added
dropwise over 30 min and the resulting solution was stirred for 30 min at 0°C. Then, the
mixture was cooled to −100°C (ether in hexane 20%, liquid N2) and a solution of (5R)-5-
{[(1R, 2S, 5R)-2-isopropyl-5-methylcyclohexyl]oxy}-4-methyl-5H-furan-2-one [14] (38b,
5 g, 20 mmol) in THF (16 ml) was added dropwise during 30 min and the resulting solution
was stirred for 30 min at −100°C. Heptanal (3.6 ml, 26 mmol) was added dropwise during
30 min and the mixture was stirred for further 30 min at −100°C. After a slow warm-up to
−20°C, the reaction was quenched with saturated NH4Cl solution (100 ml) and the mixture
was extracted with CH2Cl2 (3 × 300 ml), washed with saturated NaHCO3 solution
(3 × 100 ml) and saturated NaCl solution (3 × 100 ml), dried (MgSO4) and evaporated. The
residue was chromatographed (SiO2, 0 to 10% EtOAc in hexane) to afford 50 as a mixture of
2 diastereomers.
Yield: 1.01g, 14%.
Colorless oil, Rf 0.7 (EtOAc in hexane 50%).
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heptanal (48)
C22H38O4
Mol. Wt.: 366.53
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IR (NaCl): 3471, 2922, 1760, 1688, 1454, 1386, 1330, 1240, 1178, 1094, 943, 779, 730.
1H-NMR (400 MHz, CDCl3): δ = 5.71 (s, 1 H, H-C(5)); 4.47 (m, 1 H, H-C(1’)); 3.62 (td,
J = 8, 4 Hz, 1 H, H-C(1’’)); 2.85 (d, J = 8 Hz, 1 H, HO-C(1’1); 2.79 (d, J = 8 Hz, 1 H,
HO-C(1’2); 2.17-2.08 (m, 2 H, H-C(8’’) and Heq-C(6’’); 1.99 (s, 3 H, H3C-C(4)); 1.86-1.77
(m, 1 H, HA-C(2’)); 1.72-1.63 (m, 3 H, HB-C(2’), Heq-(3’’) and Heq(4’’)); 1.47-1.37 (m, 2 H,
H-C(5’’) and HA-C(3’)); 1.34-1.21 (m, 8 H, H-C(2’’), HB-C(3’), H2C(4’), H2C(5’), H2C(6’));
1.05-0.98 (m, 2 H, Hax-C(3’’) and Hax-C(6’’)); 0.95 (d, J = 6 Hz, 3 H, H3C(7’’)); 0.90-0.85
(m, 7 H, Hax-C(4’’), H3C(9’’) and H3C(7’)); 0.80 (d, J = 7.5 Hz, 3 H, H3C(10’’)).
13C-NMR (100 MHz, CDCl3): δ = 171.5 and 171.4 (C(2)); 155.4 (C(4)); 130.7 and 130.6
(C(3)); 101.9 and 101.0 (C(5)); 79.5 (C(1’’)); 67.0 and 66.9 C(1’)); 47.8 and 47.7 (C(2’’));
40.4 (C(6’’)); 36.7 and 36.5 (C(2’)); 34.2 (C(4’’)); 31.7 (C(5’)); 31.5 (C(5’’)); 29.0 (C(4’));
25.5 (C(3’)); 25.4 and 25.2 (C(8’’)); 23.2 and 23.1 (C(3’’)); 22.5 (C(6’)); 22.3 (C(7’’)); 20.9
and 20.8 (C(9’’)); 15.9 and 15.7 (C(10’’)); 14.1 (C(7’)); 11.5 (CH3-C(4)).
EI-MS (70 eV, 250°C): m/z (%) = 281 (11), 211 (14), 210 (12), 194 (33), 183 (33), 143 (45),
139 (80), 127 (10), 113 (28), 110 (25), 97 (24), 95 (34), 83 (100), 81 (50), 57 (38), 43 (63), 41
(56).
FAB-MS (NBA): m/z (%) = 368 (11), 367 ([M + H]+, 46), 229 (9), 212 (11), 211 (81),139
(12), 137 (15), 97 (16), 95 (12), 83 (100), 81 (22), 69 (39), 57 (29), 55 (38), 43 (23), 41 (24).
Anal. calc. for C22H38O4 (366.53): C, 72.09; H, 10.45; O, 17.46. Found: C, 72.00; H, 10.51;
O, 17.28.
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2. Synthesis of 5-hydroxy-3-(1-hydroxyheptyl)-4-methyl-5H-furan-2-one (53)
(5R)-3(1-Hydroxyheptyl)-5-{[(1R, 2S, 5R)-2-isopropyl-5-methylcyclohexyl]oxy}-4-
methyl-5H-furan-2-one (50, 4.0 g, 10.1 mmol) was dissolved in absolute CH2Cl2 (100 ml).
The solution was cooled to −78°C and BBr3 (3.1 ml, 32.7 mmol) was added. After a reaction
time of 4 hours at −78°C, additional BBr3 (3.1 ml, 32.7 mmol) was added at −78°C, the
resulting mixture was allowed to warm up to −20°C and saturated NaHCO3 solution (350 ml)
was added. After warming up to r.t., the mixture was extracted EtOAc (3 × 500 ml). The
combined organic phases were dried (MgSO4) and the solvent was evaporated. The residue
was chromatographed (SiO2, 10 to 40% EtOAc in hexane) to give 53 as a mixture of two pairs
of enantiomers.
Yield: 0.94g, 37%.
yellow oil, Rf 0.3 (EtOAc in hexane 50%).
IR (NaCl): 3370, 2929, 2857, 1747, 1683, 1456, 1386, 1336, 1181, 1123, 1091, 952, 774,
725.
1H-NMR (400 MHz, CDCl3, 1): δ =5.87 (d, J = 6 Hz, 1 H, HO-C(5A)); 5.84 (d, J = 6 Hz,1 H,
1 HO-C(5B)); 5.67 (d, J = 6 Hz, 1 H, H-C(5A)); 5.63 (d, J = 6 Hz, 1 H, H-C(5B)); 4.52-4.41
(m, 2×1 H, H-C(1’)); 3.47-3.38 (m, 1 H, HO-C(1’A)); 3.32-3.24 (m, 1 H, HO-C(1’B)); 2.07 (d,
J = 11 Hz, 2×3 H, H3C-C(4)); 1.88-1.75 (m, 2×1 H, HA-C(2’)); 1.72-1.60 (m, 2×1 H,
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 where separate resonances for the two isomers could be observed, they are labelled with superscript A and B
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HB-C(2’)); 1.44-1.19 (m, 2×8 H, H2C(3’), H2C(4’), H2C(5’) and H2C(6’)); 0.88 (t, J = 7 Hz,
2×3 H, H3C(7’)).
13C-NMR (100 MHz, CDCl3): δ = 172.1 and 171.7 (C(2)); 157.9 (C(4)); 130.4 and 129.9
(C(3)); 98.9 and 98.8 (C(5)); 66.7 and 66.6 (C(1’)); 36.2 and 35.7 (C(2’)); 31.7 (C(5’)); 28.9
(C(4’)); 25.4 (C(3’)); 22.5 (C(6’)); 14.0 (C(7’)); 11.6 and 11.4 (CH3-C(4)).
EI-MS (70 eV, 250°C): m/z (%) = 210 (9), 143 (100), 139 (43), 126 (49), 125 (53), 97 (74),
69 (45), 55 (28), 43 (80), 41 (86), 39 (38).
FAB-MS (NBA): m/z (%) = 229 ([M + H]+, 100), 211 (90), 193 (17), 137 (36), 83 (20), 55
(19), 43 (29), 41 (20).
3. Synthesis of 3-(1-hydroxyheptyl)-4-methyl-5H-furan-2-one (57)
A solution of 5-hydroxy-3(1-hydroxyheptyl)-4-methyl-5H-furan-2-one (53, 1.0 g,
4.38 mmol) in absolute MeOH (40 ml) was cooled at 0°C. NaBH4 (1.1g, 28.9 mmol) was
added in portions within 10 min and the solution was stirred for 4 hours at r.t. Then the
reaction mixture was quenched with H2O (40 ml) and extracted with CH2Cl2 (3 × 50 ml). The
combined organic layers were dried (MgSO4), and evaporated. The residue was
chromatographed (SiO2, 33% EtOAc in hexane) to give 57 as a mixture of enantiomers.
Yield: 707 mg, 76%.
colorless oil, Rf 0.3 (EtOAc in hexane 50%).
IR (NaCl): 3453, 2928, 2857, 1737, 1674, 1446, 1389, 1335, 1179, 1043, 940, 786.
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1H-NMR (400 MHz, CDCl3): δ = 4.65 (s, 2 H, H2C(5)); 4.49 (dt, J = 10, 8 Hz, 1 H, H-C(1’));
2.89 (d, J = 10 Hz, 1H, HO-C(1’)); 2.08 (s, 3 H, H3C-C(4)); 1.89-1.79 (m, 1 H, HA-C(2’));
1.73-1.62 (m, 1 H, HB-C(2’)); 1.45-1.21 (m, 8 H, H2C(3’), H2C(4’), H2C(5’) and H2C(6’));
0.88 (t, J = 7 Hz, 3 H, H-C(7’)).
13C-NMR (100 MHz, CDCl3): δ = 174 (C(2)); 157.2 (C(4)); 128.4 (C(3)); 72.7 (C(5)); 66.9
(C(1’)); 36.6 (C(2’)); 31.8 (C(5’)); 29.0 (C(4’)); 25.5 (C(3’)); 22.5 (C(6’)); 14.0 (C(7’)); 12.2
(CH3-C(4)).
EI-MS (70 eV, 250°C): m/z (%) = 194 (7), 137 (11), 127 (100), 111 (31), 110 (37), 99 (30),
43 (25), 41 (44), 39 (22).
FAB-MS (NBA): m/z (%) = 214 (12), 213 ([M + H]+, 95), 196 (13), 195 (100), 137 (22).
Anal. calc. for C12H20O3 (212.29): C, 67.89; H, 9.50; O, 22.61. Found: C, 67.53; H, 9.47;
O, 23.10.
IV Synthesis of 3-[1-hydroxydecyl]-4-methyl-5H-furan-2-one (58)
1. Synthesis of (5R)-3-(1-hydroxydecyl)-5-{[(1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl]oxy}-4-methylfuran-2(5H)-one (51)
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Mol. Wt.: 408.61
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A solution of freshly distilled diisopropylamine (2.2 ml, 15 mmol) in freshly distilled
THF (100 ml) was cooled to 0°C under argon. n-BuLi in hexane (10 ml, 15 mmol) was added
dropwise over 30 min and the resulting solution was stirred for 30 min at 0°C. Then, the
mixture was cooled to −100°C (ether in hexane 20%, liquid N2) and a solution of (5R)-5-
{[(1R, 2S, 5R)-2-isopropyl-5-methylcyclohexyl]oxy}-4-methyl-5H-furan-2-one [14] (38b,
3 g, 12 mmol) in THF (10 ml) was added dropwise during 30 min and the resulting solution
was stirred for 30 min at −100°C. Decanal (2.5 ml, 13 mmol) was added dropwise during
30 min and the mixture was stirred for further 30 min at −100°C. After a slow warm-up to
−20°C, the reaction was quenched with saturated NH4Cl solution (100 ml) and the mixture
was extracted with CH2Cl2 (3 × 100 ml), washed with saturated NaHCO3 solution
(3 × 100 ml) and saturated NaCl solution (3 × 100 ml), dried (MgSO4) and evaporated. The
residue was chromatographed (SiO2, CH2Cl2 in hexane 25%, with EtOAc from 0% to 10%) to
afford 51 as a mixture of 2 diastereomers, which can be partially separated.
Yield: 1.88g, 37%.
Light yellow oil, Rf 0.36 (EtOAc in hexane 25%).
1H-NMR (500 MHz, CDCl3): δ = 5.70 (s, 1 H, H-C(5)); 4.47 (q, 1H, J = 7.5 Hz, 1 H,
H-C(1’)); 3.62 (td, J = 10, 3.2 Hz, 1 H, H-C(1’’)); 3.13 (br s, 1 H, HO-C(1’)); 2.15-2.09 (m,
2H, H-C(8’’) and Heq(6’’)); 2.01 and 1.98 (2 s, 3 H, H3C-C(4)); 1.84-1.76 (m, 1 H, HA-C(2’));
1.71-1.63 (m, 3 H, HB-C(2’), Heq-C(3’’) and Heq-C(4’’)); 1.46-1.37 (m, 2 H, HA-C(3’) and
H-C(5’’)); 1.33-1.22 (m, 14 H, HB-C(3’), H-C(2’’), H2C(4’), H2C(5’), H2C(6’), H2C(7’),
H2C(8’) and H2C(9’)); 1.07-0.85 (m,12 H, Hax-C(3’’), Hax-C(4’’), Hax-C(6’’), H3C(5’),
H3C(7’’) and H3C(9’’); 0.808 (d, J = 7 Hz, 3 H, H3C(10’’A)) and 0.802 (d, J = 7 Hz, 3 H,
H3C(10’’B)).
13C-NMR (125 MHz, CDCl3):
Resonances of isomer A:
δ = 171.38 (C(2)); 155.40 (C(4));130.71 (C(3)); 100.65 (C(5)); 79.40 (C(1’’)); 66.82 (C(1’));
47.67 (C(2’’); 40.35 (C(6’’)); 36.43 (C(2’)); 34.15 (C(4’’)); 31.79 (C(8’)); 31.39 (C(5’’));
29.48, 29.45, 29.29, 29.23 (C(4’), C(5’), C(6’), C(7’)); 25.47 (C(3’)); 25.10 (C(8’’)); 23.02
(C(3’’); 22.60 (C(9’)); 22.19 C(7’’)); 20.80 (C(9’’)); 15.67 (C(10’’)); 14.04 (C(10’)); 11.44
(CH3-C(4)).
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Resonances of isomer B:
δ = 171.43 (C(2)); 155.37 (C(4));130.56 (C(3)); 100.81 (C(5)); 79.45 (C(1’’)); 66.91 (C(1’));
47.63 (C(2’’); 40.38 (C(6’’)); 36.57 (C(2’)); 34.15 (C(4’’)); 31.79 (C(8’)); 31.39 (C(5’’));
29.45, 29.43, 29.26, 29.23 (C(4’), C(5’), C(6’), C(7’)); 25.40 (C(3’)); 25.28 (C(8’’)); 23.15
(C(3’’)); 22.60 (C(9’)); 22.17 C(7’’)); 20.75 (C(9’’)); 15.81 (C(10’’)); 14.04 (C(10’)); 11.44
(CH3-C(4)).
EI-MS (70 eV, 200°C): m/z (%) = 281 (43), 253 (11), 252 (10), 236 (20), 225 (20), 155 (15),
143 (80), 139 (100), 126 (13), 111 (14), 110 (13), 97 (15), 95 (22), 83 (84), 81 (37), 69 (41),
67 (12), 57 (33), 55 (44), 43 (33), 41 (29).
FAB-MS (NBA): m/z (%) = 409 ([M + H]+, 29), 253 (54), 139 (11), 97 (22), 95 (18), 83
(100), 81 (28), 71 (13), 69 (48), 67 (17), 57 (43), 55 (53), 43 (33), 41 (35).
2. Synthesis of 5-hydroxy-3-(1-hydroxydecyl)-4-methyl-5H-furan-2-one (55)
(5R)-3(1-Hydroxydecyl)-5-{[(1R, 2S, 5R)-2-isopropyl-5-methylcyclohexyl]oxy}-4-
methyl-5H-furan-2-one (51, 440 mg, 1.08 mmol) was dissolved in absolute CH2Cl2 (20 ml).
The solution was cooled to −78°C and BBr3 (0.35 ml, 3.64 mmol) was added. After a reaction
time of 4 hours at −78°C, additional BBr3 (0.35 ml, 3.64 mmol) was added at −78°C, the
resulting mixture was allowed to warm up to −20°C and saturated NaHCO3 solution (50 ml)
was added. After warming up to r.t., the mixture was extracted EtOAc (3 × 50 ml). The
combined organic phases were dried (MgSO4) and the solvent was evaporated. The residue
was chromatographed (SiO2, 5 to 45% EtOAc in hexane) to give 55 as a mixture of two pairs
of enantiomers.
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Yield: 180 mg, 62%.
Light yellow oil.
1H-NMR (500 MHz, CDCl3, 2): δ = 6.17-6.12 (m, 1 H, HO-C(5)); 5.90-5.83 (m, 1 H,
H-C(5)); 4.49 (t, J = 7 Hz, 1 H, H-C(1’A)) and 4.46 (t, J = 7 Hz, 1 H, H-C(1’B)); 3.63 (br s,
1 H, HO-C(1’)); 2.08 and 2.06 (2 s, 3 H, H3C-C(4’)); 1.86-1.75 (m, 1 H, HA-C(2’)); 1.71-1.61
(m, 1 H, HB-C(2’)); 1.42-1.34 (m, 1 H, HA-C(3’)); 1.33-1.23 (m, 13 H, HB-C(3’), H2C(4’),
H2C(5’), H2C(6’), H2C(7’), H2C(8’) and H2C(9’)); 0.88 (t, J = 7 Hz, 3 H, H3C(10’)).
13C-NMR (125 MHz, CDCl3): δ = 171.82 and 171.39 (C(2)); 158.17 (C(4)); 129.76 and
129.41 (C(3)); 98.69 (C(5)); 66.10 and 65.89 (C(1’)); 35.51 and 34.95 (C(2’)); 31.42 (C(8’));
29.11 (2C), 28.93 and 28.84 (C(4’), C(5’), C(6’), and C(7’)); 25.11 C(3’)); 22.22 (C(9’));
13.66 (C(10’)); 11.30 and 11.13 (CH3C(4)).
EI-MS (70 eV, 100°C): m/z (%) = 155 (14), 153 (16), 143 (100), 139 (15), 126 (27), 125 (27),
115 (13), 97 (31), 86 (12), 71 (16), 69 (15), 57 (18), 55 (16), 43 (38), 41 (37).
FAB-MS (NBA): m/z (%) = 541 (5), 272 (16), 271 ([M + H]+, 97), 253 (100), 235 (14), 139
(11), 137 (29), 123 (11), 115 (15), 111 (13), 97 (12), 95 (14), 83 (25), 81 (16), 77 (11), 69
(31), 67 (14), 57 (18), 55 (31), 43 (28), 41 (33), 39 (14).
3. Synthesis of 3-(1-hydroxydecyl)-4-methyl-5H-furan-2-one (58)
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A solution of 5-hydroxy-3(1-hydroxydecyl)-4-methyl-5H-furan-2-one (55, 290 mg,
1.07 mmol) in absolute MeOH (10 ml) was cooled at 0°C. NaBH4 (300 mg, 7.9 mmol) was
added in portions within 10 min and the solution was stirred for 3 hours at r.t. Then the
reaction mixture was quenched with H2O (10 ml) and extracted with CH2Cl2 (3 × 10 ml). The
combined organic layers were dried (MgSO4), and evaporated to give 58 without further
purification.
Yield: 202 mg, 74%.
white amorphous solid
IR (KBr): 3452, 2919, 2851, 2364, 1720, 1669, 1467, 1441, 1385, 1345, 1182, 1083, 1043,
996, 939, 874, 780, 701, 634, 546.
1H-NMR (500 MHz, CDCl3): δ = 4.66 (br s, 2 H, H2C(5)); 4.49 (q, J = 7.5 Hz, 1 H, H-C(1’));
2.97 (d, J = 9 Hz, 1 H, HO-C(1’)); 2.08 (s, 3 H, H3C(4)); 1.88-1.80 (m, 1 H, HA-C(2’)); 1.71-
1.67 (m, 1 H, HB-C(2’)); 1.44-1.35 (m, 1 H, HA-C(3’)); 1.35-1.23 (m, 13 H, HB-C(3’),
H2C(4’), H2C(5’), H2C(6’), H2C(7’), H2C(8’), and H2C(9’)); 0.88 (t, J = 7 Hz, 3 H, H3C(10’)).
13C-NMR (125 MHz, CDCl3): δ = 174.0 (C(2)); 157.3 (C(4)); 128.2 (C(3)); 72.7 (C(5)); 66.8
(C(1’)); 36.5 (C(2’)); 31.8 (C(8’)); 29.50, 29.47, 29.31, and 29.23 (C(4’), C(5’), C(6’), and
C(7’)); 25.5 (C(3’)); 22.6 (C(9’)); 14.1 (C(10’)); 12.2 (CH3-C(4)).
EI-MS (70 eV, 100°C): m/z (%) = 128 (9), 127 (100), 110 (8), 99 (14), 41 (12).
FAB-MS (NBA): m/z (%) = 256 (14), 255 ([M + H]+, 84), 238 (17), 237 (100),167 (12), 153
(11), 137 (12), 125 (13), 95 (12), 83 (16), 81 (15), 69 (18), 67 (12), 57 (20), 55 (28), 43 (26),
41 (25).
Anal. calc. for C15H26O3 (254.37): C, 70.83; H, 10.30; O, 18.87. Found: C, 70.75; H, 10.05;
O, 18.87.
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V Miscellaneous
1. (1R, 5R, 7R, 9R)-7,9-di-tert-butyl-1-{[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]oxy}-
2,6,8-trioxa-spiro[4.5]decan-3-one (46)
colorless plates, Mp 162.3-162.7°C.
IR (KBr): 2959, 1787, 1459, 1369, 1291, 1181, 1115, 1041, 996, 948, 895.
1H-NMR (500 MHz, CDCl3): δ = 5.74 (s, 1 H, H-C(1)); 4.36 (s, 1 H, H-C(7)); 3.58 (td,
J = 11, 4.5 Hz, 1 H, H-C(1’)); 3.08 (dd, J = 12, 2 Hz, 1 H, H-C(9)); 2.58 (d, J = 17.5 Hz, 1 H,
HA-C(4)); 2.44 (d, J = 17.5 Hz, 1 H, HB-C(4)); 2.17-2.12 (m, 1 H, Heq-C(6’)); 1.98 (dd,
J = 13, 2 Hz, 1 H, HA-C(10)); 2.00-1.92 (m, 1 H, H-C(7)); 1.72-1.62 (m, 2 H, Heq-C(3’) and
Heq-C(4’)); 1.50 (dd, J = 13, 12 Hz, 1 H, HB-C(10)); 1.46-1.38 (m, 1 H, H-C(5’)); 1.22-1.16
(m, 1 H, H-C(2’)); 1.06-0.99 (m, 1 H, Hax-C(3’)); 0.97 (d, J = 7 Hz, 3 H, H3C(7’)); 0.92-0.83
(m, 2 H, Hax-C(4’) and Hax-C(6’)); 0.89 (s, 9 H, (CH3)3C(7)); 0.88 (s, 9 H, (CH3)3C(9)); 0.87
(d, J = 7 Hz, 3 H, H3C(9’)); 0.77 (d, J = 7 Hz, 3 H, H3C(10’)).
13C-NMR (125 MHz, CDCl3): δ = 175.0 (C(3)); 102.5 (C(7)); 99.8 (C(1)); 80.4 (C(9)); 79.4
(C(5)); 77.04 (C(1’)); 47.9 (C(2’)); 41.5 (C(4)); 40.1 (C(6’)); 35.1 ((CH3)3C-C(9)); 34.2
(C(4’)); 33.9 ((CH3)3C-C(7)); 31.3 (C(5’)); 27.3 (C(10)); 25.65 (C(8’)); 25.39 (3 C,
(CH3)3C-C(7)); 24.4 (3 C, (CH3)3C-C(9)); 23.0 C(3’)); 22.2 (C(7’)); 20.9 (C(9’)); 15.6
(C(10’)).
EI-MS (70 eV, 200°C): m/z (%) = 229 (22), 183 (12), 165 (13),156 (13), 155 (>100), 141
(13), 139 (18), 127 (14), 126 (17), 111 (38), 109 (10), 97 (14), 95 (14), 84 (13), 83 (71), 81
(16), 70 (10), 69 (34), 57 (39), 55 (28), 43 (22), 41 (34).
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O C25H44O5Mol. Wt.: 424.61
1
10
4
9
7
1'2'
5'
7'
8'
9' 10'
100
FAB-MS (NBA): m/z (%) = 426 (4), 425 ([M + H]+, 15), 287 (12), 201 (22), 183 (28), 165
(12), 141 (30), 139 (26), 137 (24), 99 (12), 97 (14), 95 (18), 83 (100), 81 (25), 70 (10), 69
(47), 67 (11), 57 (55), 55 (34), 43 (21), 41 (35), 39 (12).
Anal. calc. for C25H44O5 (424.61): C, 70.72; H, 10.44; O, 18.84. Found: C, 70.83; H, 10.20;
O, 18.86.
X-ray crystal data
Formula: C25H44NO5
Mol. Weight: 424.62
Crystal system: tetragonal
Space group: P 43 21 2
a [Å] 11.1355(2)
b [Å] 11.1355(2)
c [Å] 43.9984(7)
α [°] 90
β [°] 90
γ [°] 90
Z: 8
V[Å3]: 5455.8
F(000): 1872.519
Density [Mg m−3]: 1.034
µ [mm−1]: 0.070
Crystal size [mm]: 0.15 × 0.27 × 0.30
Temperature [K]: 293
Radiation: MoKα (λ = 0.71073 Å)
Θmax [°] 23.30
No of measured reflections: 19582
No of independant reflections: 3938
No of observed reflections: 2540
No of refined parameters: 272
Final R: 0.0335
Final Rw: 0.0395
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2. Data of 5-bromo-3-(1-hydroxyheptyl)-4-methyl-5H-furan-2-one (54)
Yellow oil, sensitive to air moisture, Rf 0.6 (EtOAc in hexane 50%).
IR (NaCl): 3396, 2955, 2928, 2857, 1764, 1674, 1457, 1386, 1335, 1193, 1092, 1006, 951,
779.
1H-NMR (400 MHz, CDCl3, 3): δ = 5.88 (s, 2×1 H, H-C(5)); 4.72 (d, J = 7 Hz, 1 H,
H-C(1’A)); 4.70 (d, J = 7 Hz, 1 H, HO-C(1’B); 4.56 (m, 2×1 H, H-C(1’)); 2.13 (s, 3 H,
H3C-C(4A)); 2.12 (s, 3 H, H3C-C(4B)); 1.91-1.80 (m, 2×1 H, HA-C(2)), 1.77-1.63 (m, 2×1 H,
HB-C(2)); 1.50-1.21 (m, 2×8 H, H2C(3’), H2C(4’), H2C(5’) and H2C(6’)); 0.88 (t, J = 7 Hz,
2×3 H, H3C(7’)).
13C-NMR (100 MHz, CDCl3): δ =169.9 (C(2); 159.0 (C4)); 129.5 (C(3)); 98.0 (C(5)); 66.9
(C(1’)); 35.9 (C(2’)); 31.6 (C(5’)); 28.4 (C(4’)); 25.4 (C(3’)); 22.5 (C(6’)); 14.0 (C(7’)); 12.0
(CH3-C(4)).
EI-MS (70 eV, 250°C): m/z (%) = 211 (16), 210 (18), 194 (20), 153 (25), 140 (26), 139 (74),
111 (100), 110 (99), 67 (46), 55 (43), 43 (53), 41 (94), 39 (47).
FAB-MS (NBA): m/z (%) = 293 (38), 291 ([M + H]+, 38), 275 (21), 273 (21), 211 (78), 193
(100), 137 (96), 136 (36), 107 (35), 83 (40), 77 (40), 55 (58), 43 (59), 41 (63), 39 (43).
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 where separate resonances for the two isomers could be observed, they are labelled with superscript A and B
O
O
Br
OH
54
C12H19BrO3
Mol. Wt.: 291.18
2
5
1'
7'
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Part Two
Synthesis of the putative chitinase inhibitors
I Preparation of the starting compounds 83 and 93
1. Synthesis of 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-D-
glucopyranose (83)
The preparation was carried out as described in the literature [42].
Amorphous white solid
IR (KBr): 3485, 2963, 2365, 1751, 1639, 1436, 1374, 1232, 1164, 1042, 906, 601.
EI-MS (70 eV, 200°C): m/z (%) = 331 (9), 169 (27), 157 (8), 115 (8), 109 (14), 97 (17), 43
(100).
FAB-MS (NBA): m/z (%) = 331 (32), 169 (63), 109 (35), 81 (11), 43 (100).
OO
OAc
AcO
OAc
OAc
O
OAc
AcO
AcO
OAc
OO
OAc
AcO
OAc
OH
O
OAc
AcO
AcO
OAc
82 83
mol. sieve, DMF
hydrazine acetate
C26H36O18
Mol. Wt.: 636.55
1
2
6
1'
2'
6'
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NMR data of 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-α-D-
glucopyranose (83α)4
1H-NMR (500 MHz, CDCl3): δ = 5.50 (dd, J = 10, 9.5 Hz, 1 H, H-C(3)); 5.37 (pseudo-t,
J = 3.5 Hz, 1 H, H-C(1)); 5.15 (pseudo-t, J = 9.5 Hz, 1 H, H-C(3’)); 5.08 (pseudo-t,
J = 9.5 Hz, 1 H, H-C(4’)); 4.94 (dd, J = 9.5, 8 Hz, 1 H, H-C(2’)); 4.85-4.78 (m, 1 H, H-C(2));
4.56-4.49 (m, 3 H, H-C(1’) and H2C(6)); 4.17 (ddd, J = 10, 4, 2 Hz, 1 H, H-C(5)); 4.14-4.09
(m, 2 H, H2C(6’)); 3.90-3.73 (m, 1 H, H-C(4)); 3.70-3.63 (m, 1 H, H-C(5’)); 3.52 (d, J = 3 Hz,
1 H, HO-C(1)); 2.14, 2.094, 2.079, 2.036, 2.032, 2.013, 1.99 (7s, 21 H, CH3CO).
13C-NMR (125 MHz, CDCl3): δ = 170.56, 170.44, 170.32, 170.27, 169.67, 169.30, 169.02
(7 C, CH3CO); 100.63 (C(1’)); 90.01 (C(1)); 76.47 (C(4)); 72.93 (C(3’)); 71.85 (C(5’)); 71.59
(C(2’)); 71.18 (C(2)); 69.24 (C(3)); 68.18 (C(5)); 67.75 (C(4’)); 61.70, 61.53 (C(6) and
C(6’)); 20.9-20.4 (7 C, CH3CO).
NMR data of 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-β-D-
glucopyranose (83β)4
1H-NMR (500 MHz, CDCl3): δ = 5.22 (pseudo-t, J = 9.5 Hz, 1 H, H-C(3)); 5.15 (pseudo-t,
J = 9.5 Hz, 1 H, H-C(3’)); 5.07 (pseudo-t, J = 9.5 Hz, 1 H, H-C(4’)); 4.93 (dd, J = 9.5, 8 Hz,
1 H, H-C(2’)); 4.85-4.78 (m, 1 H, H-C(2)); 4.73 (pseudo-t, J = 8 Hz, 1 H, H-C(1)); 4.56-4.49
(m, 1 H, H-C(1’)); 4.40-4.35 (m, 2 H, H2C(6)); 4.08-4.02 (m, 2 H, H2C(6’)); 3.84 (d, J = 8 Hz,
1 H, HO-C(1)); 3.80-3.72 (m, 1 H, H-C(4)); 3.70-3.63 (m, 2 H, H-C(5) and H-C(5’)); 2.15-
1.98 (7 s, 21 H, CH3CO).
13C-NMR (125 MHz, CDCl3): δ = 170.9-169.0 (7 C, CH3CO); 100.75 (C(1’)); 95.2 (C(1));
76.43 (C(4)); 73.28 (C(2)); 72.93 (C(5)); 72.86 (C(3’)); 71.90, 71.78 (C(3) and C(5’)); 71.53
(C(2’)); 67.69 (C(4’)); 61.86, 61.49 (C(6) and C(6’)); 20.9-20.4 (7 C, CH3CO).
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 Data derived from spectra of the anomer mixture
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2. Synthesis of 3-methyl-5-oxo-2,5-dihydrofuran-2-yl 2,2,2-trichloroacetimidate (93)
To a suspension of NaH (498 mg of 55% dispersion in oil, 11 mmol) in CH2Cl2 (40 ml),were
added slowly 37 [13] (9.9 g, 87 mmol) and trichloroacetonitrile (10 ml, 100 mmol). The
mixture was stirred for 4 h at r.t. and then filtered. The filtrate was evaporated, and the residue
was chromatographed on silica gel (EtOAc-hexane, 25:75) to give 93.
Yield: 14.1 g (63%)
Colorless amorphous solid, Rf 0.55 (AcOEt/hexane 1/1), sensitive to moisture.
1H-NMR (500 MHz, CDCl3): δ = 8.90 (br s, 1 H, HN=C); 6.96 (br s, 1 H, H-C(2)); 6.04-6.02
(qd, J = 1.6,1 Hz, 1 H, H-C(4)); 2.18 (dd, J = 1.6, 0.7 Hz, 3 H, H3C-C(3)).
13C-NMR (125 MHz, CDCl3): δ = 169.7 (C=O); 162.4 (C(3)); 160.8 (C=NH), 119.7 (C(4));
97.7 (C(2)); 90.0 (CCl3); 13.3 (CH3-C(3)).
EI-MS (70 eV, 100°C): m/z (%) = 232 (1.5), 230 (4), 228 (4), 110 (12), 108 (18), 97 (100), 69
(16), 68 (13), 41 (28), 40 (11), 39 (17).
FAB-MS (NBA): m/z (%) = 262 (1.6), 260 (5), 258 ([M + H]+, 5), 250 (14), 137 (14), 136
(12), 107 (7), 98 (14), 97 (100), 89 (7), 77 (8), 41 (8), 39 (7).
Anal. calc. for C7H6Cl3NO3 (258.49): C 32.53, H 2.34, N 5.42; found: C 32.56, H 2.48,
N 5.47.
O
O
O
Cl3C
HN
93
O
O
HO
37
CCl3CN, NaH
CH2Cl2, r.t.
C7H6Cl3NO3
Mol. Wt.: 258.492
5
3
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II Synthesis of the glycosylated furanones 92, 96, 97, 101 and 102
1. Synthesis of 4-methyl-5-(2,3,4,6-tetra-O-acetyl-D-glucopyranosyloxy)-5H-furan-2-one
(92)
2,3,4,6-Tetra-O-acetyl-D-glucopyranose [38] (77; 8.16 g, 23 mmol) and 93 (8.5 g, 33 mmol)
were dissolved at r.t. in anhydrous CH2Cl2 (150 ml). TMSOTf (5.0 ml, 28 mmol) was added
and the mixture was stirred for 5 hours at r.t. Then it was washed with H2O (30 ml), dried
(MgSO4), filtered and the solvent was evaporated. The residue was chromatographed (SiO2,
0 to 5% MeOH in CH2Cl2) to give 92 as a mixture of 4 diastereomers.
Yield: 7.41 g (70%)
13C-NMR (125 MHz, CDCl3): δ = 170.6-168.7 (C=O); 163.65, 163.36, 162.35, 161.88
(C(4)); 119.9-118.9 (C(3)); 103.5-88.9 (C(5) and C(1’)); 72.5-67.7 (C(2’), C(3’), C(4’), and
C(5’)); 61.7-61.3 (C(6’)); 20.7-20.3 (CH3-CO); 13.32, 13.29, 13.21, 12.99 (CH3-C(4)).
OAcO
OAc
AcO
OAc
O
O
O
92
O
O
O
Cl3C
HN
93
OAcO
OAc
AcO
OAc
OH
77
+
TMSOTf
CH2Cl2
C19H24O12
Mol. Wt.: 444.39
2
51'2'
6'
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Isolation of one of the β-isomers: from some fractions of the chromatography of 92.
4-methyl-5-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-5H-furan-2-one.
White amorphous solid.
1H-NMR (500 MHz, CDCl3): δ = 5.97 (br s, 1 H, H-C(5)); 5.89 (qd J = 1.5, 1 Hz, 1 H,
H-C(3)); 5.24 (pseudo-t, J = 10 Hz, 1 H, H-C(3’)); 5.12 (pseudo-t, J = 10 Hz, 1 H, H-C(4’));
5.05 (dd, J = 10, 8 Hz, 1 H, H-C(2’)); 4.94 (d, J = 8 Hz, 1 H, H-C(1’)); 4.27 (dd, J = 12.5,
5 Hz, 1 H, HA-C(6’)); 4.19 (dd, J = 12.5, 2.5 Hz, 1 H, HB-C(6’)); 3.79 (ddd, J = 12.5, 5,
2.5 Hz, 1 H, H-C(5’)); 2.10 (s, 3 H, H3C-CO); 2.08 (dd, J = 1.5, 0.5 Hz, 3 H, H3C-C(4)); 2.05,
2.03, 2.00 (3 s, 9 H, H3C-CO).
13C-NMR (125 MHz, CDCl3): δ = 170.5, 170.2, 170.0, 169.44, 169.41 (C=O); 163.4 (C(4)),
119.0 (C(3)); 99.5 (C(5)); 98.1 (C(1’)); 72.49 (C(3’)); 72.35 (C(5’)); 70.6 (C(2’)); 68.1
(C(4’)); 61.7 (C(6’)); 20.70, 20.59, 20.55, 20.54 (CH3-CO); 13.3 (CH3-C(4)).
EI-MS (70 eV, 350 °C): m/z (%) = 347 (4), 331 (4), 259 (13), 245 (20), 169(7), 157(21), 139
(28), 115 (8), 98 (26), 97 (73), 69 (7), 43 (100), 41 (10).
FAB-MS (NBA): m/z (%) = 445 ([M + H]+, 8), 331 (48), 169 (76), 137 (27), 136 (15), 127
(12), 109 (41), 107 (10), 97 (38), 89 (12), 77 (14), 43 (100), 41 (12), 39 (11).
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2. Synthesis of 5-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-D-glucopyranosyloxy)-4-methyl-
5H-furan-2-one (96a-d)
Â
2.1 Synthesis and separation of the isomers
2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-D-glucopyranose [40]5 (81, 3.41 g, 9.8 mmol) and
5-trichloroacetimidate-4-methyl-5H-furan-2-one (93; 5.25 g, 20 mmol) were dissolved at r.t.
in anhydrous CH2Cl2 (300 ml). TMSOTf (3.4 ml, 19 mmol) was added and the mixture was
stirred overnight at r.t. Then it was washed with H2O (50 ml), dried (MgSO4), filtered and the
solvent was evaporated. The residue was chromatographed (200 mm × 55 mm i.d., SiO2,
0-3% MeOH in CH2Cl2). Fractions containing the same isomer according to TLC were pooled
to give 96a (265 mg, 6%), 96b (123 mg, 3%), 96c (630 mg, 14%), and 96d (160 mg, 4%); the
remaining fractions contained mixtures of isomers (678 mg, 16%).
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 The hydrolysis of the chloride was carried out using NaHCO3 instead of Ag2CO3 giving the same yield.
O
O
O
Cl3C
HN
93
OAcO
NHAc
AcO
OAc
O
O
O
96
+OAcO
NHAc
AcO
OAc
OH81
CH2Cl2
2
51'2'
6'BF3·Et2O
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2.2 Data of (5R*)-5-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyloxy)-4-
methyl-5H-furan-2-one (96a)
light brown amorphous solid, Rf 0.39 (5% MeOH in CH2Cl2 )
[α]D20: +92.2 (589 nm), +96.3 (578 nm), 108.8 (546 nm), +181.7 (436 nm) (c = 1.09 CH2Cl2).
IR (KBr): 3363, 2958, 1750, 1674, 1538, 1441, 1375, 1232, 1128, 1047, 964, 892.
1H-NMR (500 MHz, CDCl3): δ = 6.00-5.99 (m, 1H, H-C(3)); 5.89 (s, 1 H, H-C(5)); 5.66 (d,
J = 9.5 Hz, 1 H, H-N); 5.29 (d, J = 3.5 Hz, 1 H, H-C(1’)); 5.20-5.14 (m, 2 H, H-C(3’) and
H-C(4’)); 4.46 (m, 1 H, H-C(2’)); 4.24 (dd, J = 12.5, 5 Hz, 1 H, HA-C(6’)); 4.15 (dd, J = 12.5,
2.5 Hz, 1 H, HB-C(6’)); 4.06 (ddd, J = 9.5, 5, 2.5 Hz, 1 H, H-C(5’)); 2.14-2.13 (br s, 3 H,
H3C-C(4)); 2.107, 2.051, 2.037, 1.972 (4 s, 12 H, H3C-CO).
13C-NMR (125 MHz, CDCl3): δ = 171.28, 170.55, 170.29, 169.67, 169.14 (C=O); 162.0
(C(4)); 120.0 (C(3)); 100.3 (C(5)); 97.0 (C(1’)); 70.3 (C(3’)); 69.0 (C(5’)); 67.9 (C(4’)); 61.9
(C(6’)); 51.2 (C(2’)); 23.09, 20.66, 20.64, 20.54 (CH3-CO); 13.4 (CH3-C(4)).
EI-MS (70 eV, 200°C ): m/z (%) = 346 (8), 330 (5), 318 (22), 304 (18), 286 (26), 259 (43),
244 (36), 226 (14), 198 (14), 184 (27), 168 (16), 166 (40), 157 (18), 156 (88), 150 (16), 142
(17), 140 (10), 139 (98), 138 (44), 126 (12), 114 (56), 101 (12), 98 (16), 97 (100), 96 (50), 84
(10), 69 (14), 60 (10), 43 (79), 41 (12).
FAB-MS (NBA): m/z (%) = 444 ([M + H]+, 36), 330 (63), 270 (14), 210 (38), 168 (43), 150
(72), 126 (22), 108 (30), 97 (55), 43 (100).
OAcO
AcO
OAc
NH
Ac O O O
96a
α
5
(R*)
C19H25NO11
Mol. Wt.: 443.40
2
2' 1'
6'
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2.3 Data of (5S*)-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyloxy)-4-
methyl-5H-furan-2-one (96b)
Amorphous solid, containing some 96a and 96c; Rf 0.35 (5% MeOH in CH2Cl2).
1H-NMR (500 MHz, CDCl3): δ = 5.96 (d, J = 9.5 Hz, 1 H, H-N); 5.93 (dd, J = 1.6, 1.0 Hz,
1 H, H-C(3)); 5.77 (s, 1 H, H-C(5)); 5.26 (d, J = 3.5 Hz, 1 H, H-C(1’)); 5.18-5.06 (m, 2 H,
H-C(3’) and H-C(5’)); 4.29 (ddd, J = 10.6, 8.5, 3.7 Hz, 1 H, H-C(2’)); 4.24-4.19 (m, 1 H,
H-C(4’)); 4.18-4.09 (m, 2 H, H2C(6’)); 2.093, 2.065, 2.014, 2.011, 1.937 (5 s, 15 H, CH3).
13C-NMR (125 MHz, CDCl3): δ = 171.61, 170.70, 170.12, 169.71, 169.12 (C=O); 162.3
(C(4)); 119.6 (C(3)); 103.1 (C(5)); 97.9 (C(1’)); 70.4 (C(3’)); 69.0 (C(4’)); 67.4 (C(5’)); 61.5
(C(6’)); 52.3 (C(2’)); 22.87, 20.6 (2 C), 20.5 (CH3CO); 13.2 (CH3-C(4)).
2.4 Data of (5R)-5-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyloxy)-4-
methyl-5H-furan-2-one (96c)
Colorless needles; Mp 162°C; Rf 0.30 (5% MeOH in CH2Cl2).
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[α]D20: −43.1 (589 nm), −44.9 (578 nm), −51.1 (546 nm), −88.3 (436 nm) (c=1.07 CH2Cl2).
IR (KBr): 3271, 3108, 2958, 2364, 2345, 1797, 1747, 1676, 1654, 1560, 1437, 1369, 1295,
1224, 1127, 1082, 1034, 967, 888 cm−1.
1H-NMR (500 MHz, CDCl3): δ = 5.99 (br s, 1 H, H-C(5)); 5.90-5.85 (br s, 1 H, H-N); 5.88
(qd, J = 1.5, 1 Hz, 1 H, H-C(3)); 5.20 (pseudo-t, J = 10 Hz, 1 H, H-C(3’)); 5.12 (pseudo-t,
J = 10 Hz, 1 H, H-C(4’)); 4.96 (d, J = 8.5 Hz, 1 H, H-C(1’)); 4.26 (dd, J = 12.5, 4.5 Hz, 1 H,
HA-C(6’)); 4.21 (dd, J = 12.5, 2.5 Hz, 1 H, HB-C(6’)); 4.15 (ddd, J = 10.5, 9.4, 8.6 Hz, 1 H,
H-C(2’)); 3.80 (ddd, J = 10, 4.5, 2.5 Hz, 1 H, H-C(5’)); 2.11 (s, 3 H, H3C-CO-O-C(6’)); 2.09
(dd, J = 1.6, 0.6 Hz, 3 H, H3C-C(4)); 2.04 (2 s, 6 H, H3C-CO); 1.94 (s, 3 H, H3C-CO-NH).
13C-NMR (125 MHz, CDCl3): δ = 170.95, 170.62, 170.47, 170.43, 169.3 (C=O); 163.9
(C(4)); 118.8 (C(3)); 99.9 (C(5)); 98.7 (C(1’)); 72.42 (C(3’)); 72.36 (C(5’)); 68.2 (C(4’)); 61.8
(C(6’)); 53.6 (C(2’)); 23.2 (CH3-CO-NH); 20.72, 20.61, 20.58 (CH3-CO); 13,4 (CH3-C(4)).
EI-MS (70 eV, 400°C): m/z (%) = 346 (3), 318 (5), 304 (6), 286 (7), 259 (10), 244 (11), 184
(7),166 (17), 156 (31), 139 (31),138 (17), 114 (22), 97 (54), 96 (25), 84 (9), 69 (9), 43 (100),
41 (14).
FAB-MS (NBA): m/z (%) = 444 ([M + H]+, 21), 330 (64), 210 (19), 168 (32), 150 (45), 136
(17), 126 (17), 108 (25), 97 (48), 90 (12), 89 (15), 77 (17), 73 (37), 63 (9), 51 (12), 43 (100),
41 (11), 39 (15).
Anal. calc. for C19H25NO11 (443.40): C 51.47, H 5.68, N 3.16, O 39.69; found: C 51.27,
H 5.56, N 3.00, O 39.66.
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2.5 Data of (5S)-5-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyloxy)-4-
methyl-5H-furan-2-one (96d)
Colorless blocks; Mp 168-169°C; Rf 0.23 (5% MeOH in CH2Cl2)
[α]D20: +15.1 (589 nm), +15.9 (578 nm), +17.9 (546 nm), +30.4 (436 nm) (c = 1.01 CH2Cl2).
IR (KBr): 3356, 3116, 2958, 1748, 1698, 1660, 1534, 1436, 1375, 1245, 1078, 1042, 967, 889
cm−1.
1H-NMR (500 MHz, CDCl3): δ = 6.69 (d, J = 9 Hz, 1 H, H-N); 5.97 (s, 1 H, H-C(5)); 5.91
(qd, J = 1.5, 1 Hz, 1 H, H-C(3)); 5.35 (dd, J = 10.5, 9.5 Hz, 1 H, H-C(3’)); 5.03 (dd, J = 10,
9.5 Hz, 1 H, H-C(4’)); 4.98 (d, J = 10 Hz, 1 H, H-C(1’)); 4.17-4.15 (m, 2 H, H-C(6’)); 4.01
(pseudo-dt, J = 10.5, 8.5 Hz, 1 H, H-C(2’)); 3.81 (ddd, J = 10, 4.5, 3 Hz, 1 H, H-C(5’)); 2.14
(dd, J = 1.6, 0.6 Hz, 3 H, H3C-C(4)); 2.09, 2.03, 2.02, 2.01 (4 s, 12 H, H3C-CO).
13C-NMR (125 MHz, CDCl3): δ = 170.9, 170.52, 170.44, 170.10, 169.3 (C=O); 164.5 (C(4));
119.2 (C(3)); 101.7 (C(5)); 95.8 (C(1’)); 71.94, 71.86 (C(3’) and C(5’)); 68.4 (C(4’)); 61.9
(C(6’)); 54.0 (C(2’)); 23.1, 20.59, 20.53, 20.46 (CH3-CO); 13.5 (CH3-C(4)).
EI-MS (70 eV, 200°C): m/z (%) = 346 (4), 318 (11),304 (17), 286 (16), 259 (31), 244 (28),
184 (22), 166 (41), 156 (72), 139 (80), 114 (49), 97 (100), 43 (74).
FAB-MS (NBA): m/z (%) = 445 (7.2), 444 ([M + H]+, 30), 330 (79), 270 (7), 210 (25), 168
(36), 150 (51), 126 (19), 108 (23), 97 (48), 43 (100).
OAcO
AcO
OAc
NHAc
O
O
O
96dβ
5 (S)
C19H25NO11
Mol. Wt.: 443.40
2
1'
2'
6'
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Anal. calc. for C19H25NO11 (443.40): C 51.47, H 5.68, N 3.16, O 39.69; found: C 51.20,
H 5.62, N 3.24, O 39.67.
X-ray crystal data
Formula: C19H25NO11
Mol. Weight: 443.42
Crystal system: monoclinic
Space group: P 21
a [Å] 9.5269(4)
b [Å] 9.7034(9)
c [Å] 11.8179(7)
α [°] 90
β [°] 98.059(5)
γ [°] 90
Z: 2
V[Å3]: 108170(13)
F(000): 468
Density [Mg m−3]: 1.361
µ [mm−1]: 0.113
Crystal size [mm]: 0.18 × 0.20 × 22
Temperature [K]: 173
Radiation: MoKα (λ = 0.71073 Å)
Θmax [°] 31.996
No of measured reflections: 66999
No of independant reflections: 3954
No of reflections in refinement: 3153
No of variables: 281
Final R: 0.0407
Final Rw: 0.0598
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3. Synthesis of 4-methyl-5-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosyl)-D-glucopyranosyloxy]-5H-furan-2-one(97)
3.1 Preparation
To a solution of 2,3,6-tri-O-acetyl-4-O-(2,3,4,6–tetra-O-acetyl-β-D-glucopyranosyl)-D-
glucopyranose (1.774 g, 2.8 mmol) and 3-methyl-5-oxo-2,5-dihydrofuran-2-yl 2,2,2-
trichloroacetimidate 93 (2.496 g, 9.7 mmol) in CH2Cl2 (100 ml), was added TMSOTf (0.8 ml,
4.4 mmol). The mixture was stirred overnight at r.t., then H2O (30 ml) was added. The
organic phase was dried (MgSO4), filtered, and the solvent was evaporated. The residue was
flash-chromatographed (SiO2, gradient of EtOAc-hexane, 25:75 to EtOAc) to give 97 (1.30 g,
64%) as a mixture of 4 diastereomers.
3.2 Data of the mixture of all isomers
Colorless amorphous solid; Rf 0.5-0.6 (EtOAc).
13C-NMR (125 MHz, CDCl3): δ = 170.3-168.8 (C=O); 163.44, 163.16, 162.29, 162.01
(C(4)); 119.79, 119.46, 119.29, 118.92 (C(3)); 103.64, 101.99, 100.76, 100.65, 100.53,
100,49, 100.36, 99.70, 97.98, 97.19, 96.77, 94.6 (C(5), C(1’) and C(1’’)); 76.34, 75.98, 75.93,
75.87 (C(4’)); 73.1-68.8 (C(2’), C(3’), C(5’), C(2’’), C(3’’), C(5’’)); 67.63, 67.61, 67.58,
67.53 (C(4’’)); 61.5-61.2 (C(6’) and C(6’’)); 20.9-20.3 (CH3-CO); 13.35, 13.22, 13.10, 12.96
(CH3-C(4)).
OO
OAc
AcO
OAc
O
O
O
OAcO
OAc
AcO
OAc
97
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OAc
AcO
OAc
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O
OAc
AcO
AcO
OAc
83
93,TMSOTf
CH2Cl2
C31H40O20
Mol. Wt.: 732.64
2
1'
2'
6'
1''
2''
6''
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EI-MS (70 eV, 300°C): m/z (%) = 385 (29), 331 (33), 317 (13), 271 (6), 229 (6), 169 (100),
109 (36), 97 (52), 43 (52).
FAB-MS (NBA): m/z (%) = 733 ([M + H]+, 0.9), 619 (5), 331 (17), 169 (49), 127 (9), 109
(31), 97 (15), 43 (100).
3.3 Data of 4-methyl-5-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6–tetra-O-acetyl-β-D-glucopyranosyl)-
α-D-glucopyranosyloxy]-4-methyl-5H-furan-2-one.
White amorphous solid; Rf 0.54 (EtOAc).
[α]D20: +43.4 (589 nm), +45.4 (578 nm), +51.0 (546 nm), +83.1 (436 nm), +120.8 (365 nm)
(c = 1.06 CH2Cl2).
IR (KBr): 3482, 2962, 1753, 1658, 1439, 1374, 1230, 1154, 1045, 966, 894.
1H-NMR (500 MHz, CDCl3): δ = 5.96-5.95 (br s, 1 H, H-C(2)); 5.74 (s, 1 H, H-C(5)); 5.41
(pseudo-t, J = 10 Hz, 1 H, H-C(3’)); 5.36 (d, J = 4 Hz, 1 H, H-C(1’)); 5.15 (pseudo-t,
J = 10 Hz, 1 H, H-C(3’’)); 5.07 (pseudo-t, J = 10 Hz, 1 H, H-C(4’’)); 4.92 (pseudo-t,
J = 10 Hz, 1 H, H-C(2’’)); 4.84 (dd, J = 10, 4 Hz, 1 H, H-C(2’)); 4.57 (d, J = 11 Hz, 1 H,
HA-C(6‘)); 4.40 (dd, J = 12.5, 4.5 Hz, 1 H, HA-C(6’’)); 4.15-4.08 (m, 2 H, HB-C(6’) and
H-C(5’)); 4.04 (d, J = 12.5 Hz, 1 H, HB-C(6’’)); 3.76 (pseudo-t, J = 10 Hz, 1 H, H-C(4’));
3.68 (ddd, J = 10, 4, 2Hz, 1 H, H-C(5’’)); 2.170, 2.088, 2.076, 2.056, 2.045, 2.039, 2.011,
1.982 (8 s, 24 H, CH3-C(4) and CH3-CO).
13C-NMR (125 MHz, CDCl3): δ = 170.31, 170.19, 170.05, 170.00, 169.70, 169.47, 169.15,
169.08 (C=O); 162.3 (C(4)); 119.4 (C(3)); 103.6 (C(5)); 100.6 (C(1’’)); 96.8 (C(1’)); 76.0
(C(4’)); 72.8 (C(3’’)); 71.7 (C(5’’)); 71.3 (C(2’’)); 70.5 (C(2’)); 69.5 (C(5’)); 69.0 (C(3’));
67.6 (C(4’’)); 61.4 (C(6’’)); 61.2 (C(6’)); 20.7-20.3 (CH3-CO); 12.9 (CH3-C(4)).
EI-MS (70 eV, ca. 300°C): m/z (%) = 431 (4), 385 (37), 331 (29), 317 (17), 271 (5), 243 (7),
242 (6), 169 (100), 109 (35), 97 (54), 43 (43).
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FAB-MS (NBA): m/z (%) = 734 (2.3), 733 ([M + H]+, 4.7), 619 (5), 331 (31), 169 (54), 109
(30), 97 (36), 43 (100).
4. Synthesis of 5-(D-glucopyranosyloxy)-4-methyl-5H-furan-2-one (101)
To a solution of 92 (1097 mg, 2.5 mmol) in EtOH-CH2Cl2 (9:1, 30 ml), was added
guanidine (114 mg, 1.9 mmol) in EtOH-CH2Cl2 (9:1, 2 ml). After a reaction time of 1.5 h at
r.t., additional guanidine (284 mg, 4.8 mmol) in EtOH-CH2Cl2 (9:1, 5 ml) was added. Each
hour, additional guanidine (57 mg, 0.95 mmol) in EtOH-CH2Cl2 (9:1, 1 ml) was added. The
reaction was followed by TLC until the presence of glucose was detected. Then, the mixture
was poured directly onto a silica gel column (0 to 10% MeOH in CH2Cl2). A mixture of
isomeric 101 (219 mg, 32%) containing partially deacetylated compounds was isolated.
13C-NMR (125 MHz, CD3OD): δ = 173.14, 173.04, 172.99, 172.92, 172.84 (C=O); 167.19,
167.13, 166.63, 166.31 (C(4)); 119.72, 119.41, 118.98, 118.93 (C(3)); 105.6, 105.1, 103.4,
102.1, 101.84, 101.80, 100.7, 98.6, 98.0, 93.8 (C(5) and C(1’)); 78.35, 78.32, 77.71, 77.67,
76.02, 75.09, 74.98, 74.68, 74.60, 74.53, 74.47, 74.37, 73.58, 73.07, 72.56, 71.8, 71.5, 71.3,
70.87, 70.85, 70.46 (C(2’), C(3’),C(4’), and C(5’)); 62.62, 62.50, 62.24, 61.74 (C(6’)); 13.62,
13.55, 13.46, 13.37 (CH3-C(4)).
OAcO
OAc
AcO
OAc
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O
O
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OHO
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guanidine
MeOH/CH2Cl2  9:1
C11H16O8
Mol. Wt.: 276.241'
2'
6' 2
5
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5. Synthesis of 5-(2-acetamido-2-deoxy-D-glucopyranosyloxy)-4-methyl-5H-furan-2-one
(102)
To a solution of 5-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-D-glucopyranosyloxy)-4-
methyl-5H-furan-2-one 96 (199 mg, 0.45 mmol) in EtOH-CH2Cl2 (90:10, 5 ml), was added
guanidine (56 mg, 0.95 mmol) in EtOH-CH2Cl2 (90:10, 1 ml). After a reaction time of 1.5h at
r.t., guanidine (56 mg, 0.95 mmol) in EtOH-CH2Cl2 (90:10, 1 ml) was added. The mixture
was stirred for 2 h at r.t., and then poured directly onto a silica gel column. Elution with 10%
MeOH in CH2Cl2 gave a mixture of isomeric 5-(2-acetamido-2-deoxy-D-glucopyranosyloxy)-
4-methyl-5H-furan-2-one 102 (43 mg, 30%), consisting of three stereoisomers.
White amorphous solid; Rf 0.3 (20% MeOH in CH2Cl2).
13C-NMR (125 MHz, CD3OD): δ = 173.88, 173.82, 173.64 (CH3-CO-NH); 172.91, 172.85,
172.77 (C(2)); 166.68 (2 C), 166.14 (C(4)); 119.77, 119.27, 119.25 (C(3)); 105.29, 102.34,
101.54 (C(5)); 100.97, 99.84, 97.69 (C(1’)); 78.53, 75.64, 75.28, 74.62, 71.98, 71.84, 71.52
(C(3’), C(4’) and C(5’)); 62.69, 62.58, 61.85 (C(6’)); 56.92, 55.27, 54.80 (C(2’)); 22.94,
22.50 (2 C) (CH3-CO); 13.55, 13.36, 13.33 (CH3-C(4)).
EI-MS (70 eV, 250°C): m/z (%) = 244 (4), 220 (3), 202 (16), 156 (13), 142 (19), 130 (76),
114 (47), 102 (35), 97 (92), 88 (26), 60 (100), 43 (75).
FAB-MS (NBA): m/z (%) = 319 (7), 318 ([M + H]+], 40), 264 (6), 204 (49), 102 (100), 97
(26), 60 (35), 43 (27).
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5
117
III Miscellaneous
1. Synthesis of (5S)-5-{[(1S,2R,5R)-2-isopropyl-5-methylcyclohexyl]oxy}-4-methyl-5H-
furan-2-one (104)
To a solution of 5-hydroxy-4-methyl-5H-furan-2-one 37 [13] (6.63 g, 58 mmol) in
toluene (20 ml), (1S, 2R, 5R)-2-isopropyl-5-methylcyclohexanol ((+)-isomenthol, 10g,
64 mmol) and a catalytic amount of p-toluenesulfonic acid were added. The solution was
refluxed overnight (a dropping funnel filled with molecular sieve 4Å was put between the
reaction flask and the condenser). After cooling at r.t., the mixture was washed with saturated
NaHCO3 solution (3 × 20 ml) and saturated NaCl solution (3 × 20 ml). The organic phase was
dried (MgSO4), filtered and evaporated. The product was purified by successive
recrystallizations in pentane.
Yield: 729 mg, 11%.
Colorless needles, Mp 63°C.
IR (KBr): 3099, 2924, 1756, 1656, 1442, 1352, 1295, 1127, 912, 729, 569, 507.
1H-NMR (500 MHz, CDCl3): δ = 5.85 (br s, 1 H, H-C(2)); 5.75 (s, 1 H, H-C(5)); 4.00 (td,
J = 6, 3 Hz, 1 H, H-C(1’)); 2.05 (dd, J = 1.5 0.5 Hz, 3 H, H3C-C(4)); 1.94-1.79 (m, 2 H,
H-C(8’) and H-C(5’)); 1.69-1.57 (m, 2 H, Heq-C(3’) and Heq-C(6’)); 1.55-1.41 (m, 3 H,
Hax-C(3’), Heq-C(4’), and Hax-C(6’)); 1.40-1.34 (m, 1 H, H-C(2’)); 1.26-1.17 (m, 1 H,
Hax-C(4’)); 0.92 and 0.91 (2 d, J = 7 Hz, 6 H, H3C(7’) and H3C(9’)); 0.88 (d, J = 7 Hz, 3 H,
H3C(10’)).
O O O
104
1'2'
5'
7'
8'
9'
10'
3
5
C15H24O3
Mol. Wt.: 252.35OHO O
37
    (+)-isomenthol, 
p-toluenesulfonic acid
toluene, reflux
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13C-NMR (125 MHz, CDCl3): δ = 171.2 (C(2)); 163.8 (C(4)); 118.8 (C(3));102.5 (C(5)); 77.4
(C(1’)); 46.3 (C(2’)); 35.2 (C(6’)); 29.8 (C(4’)); 27.2 (C(5’)); 25.8 (C(8’)); 20.93 and 20.80
(C(7’) and C(9’)); 20.42 (C(3’)); 19.0 (C(10’)); 13.3 (CH3-C(4)).
EI-MS (70 eV, 50°C): m/z (%) = 167 (7), 138 (39), 137 (22), 98 (55), 97 (100), 95 (30), 93
(13), 81 (47), 69 (29), 55 (18), 41 (22).
FAB-MS (NBA): m/z (%) = 505 (7), 254 (6), 253 ([M + H]+, 37), 139 (63), 137 (17), 115
(100), 97 (43), 95 (11), 83 (96), 81 (21), 69 (34), 57 (33), 55 (32), 43 (15), 41 (28).
Anal. calc. for C15H24O3 (252.35): C, 71.39; H, 9.59; O, 19.02. Found: C, 71.40; H, 9.65;
O, 19.16.
2. Synthesis of (5S)-5-{[(1S,2R,5S)-2-isopropyl-5-methylcyclohexyl]oxy}-4-methyl-5H-
furan-2-one (106)
Preparation
To a solution of (1S,2R,5S)-2-isopropyl-5-methylcyclohexanol ((+)-menthol, 2.023 g,
13 mmol) and a catalytic amount of p-toluenesulfonic acid in toluene (10 ml), a solution of
5-hydroxy-4-methyl-5H-furan-2-one 37 [13] (1.016 g, 8.9 mmol) in toluene (2 ml) was added
dropwise. The mixture was refluxed overnight (a dropping funnel filled with molecular sieve
4Å was put between the reaction flask and the condenser). After cooling at r.t., the mixture
was washed with saturated NaHCO3 solution (3 × 20 ml) and saturated NaCl solution
(3 × 20 ml). The organic phase was dried (MgSO4), filtered and evaporated. Petrol ether was
added to the residue and the mixture was left in the freezer (−18°C) overnight. The obtained
O O O
106
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C15H24O3
Mol. Wt.: 252.35OHO O
37
    (+)-menthol, 
p-toluenesulfonic acid
toluene, reflux
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crystals were filtrated and the product was purified after two successive recrystallization in
petrol ether.
Yield: 179 mg, 8%.
colorless needles, Mp 98.8-99.2°C.
[α]D20 = +161.2 (589 nm), +167.7 (578 nm), +190.5 (546 nm); +325.9 (436 nm), +526.9
(365 nm) (c = 1.07, CH2Cl2).
IR (KBr): 2957, 2925, 2866, 2372, 1747, 1655, 1457, 1370, 1346, 1296, 1241, 1156, 1121,
952, 901, 861, 733, 628, 575.
1H-NMR (500 MHz, CDCl3): δ = 5.84 (br s, 1 H, H-C(3)); 5.78 (s, 1 H, H-C(5)); 3.64 (td,
J = 10.5, 4.5 Hz, 1 H, H-C(1’)); 2.16-2.09 (m, 2 H, H-C(8’) and Heq-C(6’)); 2.04 (dd, J = 1.6,
0.6 Hz, 3 H, H3C-C(4)); 1.72-1.63 (m, 2 H, Heq-C(4’) and Heq-C(3’)); 1.47-1.37 (m, 1 H,
H-C(5’)); 1.29-1.22 (m, 1 H, H-C(2’)); 1.08-0.85 (m, 3 H, Hax-C(3’), Hax-C(4’), and
Hax-C(6’)); 0.95 (d, J = 6.5 Hz, 3 H, H3C(7’)); 0.87 (d, J = 7 Hz, 3 H, H3C(9’)); 0.81 (d,
J = 7 Hz, 3 H, H3C(10’)).
13C-NMR (125 MHz, CDCl3): δ = 171.2 (C(2)); 163.8 (C(4)); 118.8 (C(3)); 101.6 (C(5));
79.4 (C(1’)); 47.7 (C(2’)); 40.4 (C(6’)); 34.2 (C(4’)); 31.4 (C(5’)); 25.2 (C(8’)); 23.1 (C(3’));
22.2 (C(7’)); 20.9 (C(9’)); 15.7 (C(10’)); 13.3 (CH3-C(4)).
EI-MS (70 eV, 50°C): m/z (%) = 167 (7), 138 (48), 137 (27), 123 (15), 115 (10), 98 (52), 97
(100), 95 (36), 83 (17), 82 (11), 81 (62), 69 (31), 55 (23), 43 (12), 41 (30).
FAB-MS (NBA): m/z (%) = 505 (7), 254 (7), 253 ([M + H]+, 42), 139 (47), 137 (14), 115
(100), 97 (39), 95 (10), 83 (85), 81 (20), 69 (31), 57 (31), 55 (32), 43 (16), 41 (27).
Anal. calc. for C15H24O3 (252.35): C, 71.39; H, 9.59; O, 19.02. Found: C, 71.42; H, 9.29;
O, 18.92.
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C. Summary
Bacteria are able to communicate through chemical signals. They can for instance
estimate their population by the use of signalling compounds: this phenomenon is called
quorum sensing. Some of these signalling compounds are derivatives of homoserine lactones.
When their concentration reaches a certain level, bacterial genes are triggered, which leads to
virulence, bacterial film formation, and so on. Natural halogenated furanones 22 and 23
extracted from the marine alga Delisea pulchra proved to inhibit the quorum sensing. Other
natural furanones 24a-27a extracted from Streptomyces antibioticus TÜ 99 were also quorum
sensing inhibitors. As the structures of these natural compounds were similar to the
homoserine lactones, additional furanones were synthesized in order to investigate their
properties towards the quorum sensing.
Following the synthetic route published by Grossmann [11], the compounds 56a, 56b,
and 58 were prepared. The key step of the synthesis, which is a condensation of the
menthylated furanone 38b and an aldehyde with LDA under kinetic conditions, was
optimized. The biological activity of these three compounds, as well as of all intermediates,
was investigated. The tests were carried out with a mutant strain of Chromobacterium
violaceum, called CV026.
Some of the synthetic furanones proved indeed to be weak quorum sensing inhibitors,
however none of them was more active than the natural compound 22 [22]. In addition, some
of these compounds were toxic for Chromobacterium violaceum.
The Grossmann method, followed by a reduction of the side chain, was also used for
the preparation of the flavour furanone 64, which had previously shown a weak inhibition of
O
O OH
O
O OH
O
O OH
5856a 56b
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the pristinamycin production by Streptomyces pristinaespiralis. Further tests were carried out
with mammalian cells, but the compound 64 proved to be toxic [21].
Other biological tests showed that some menthylated furanones were weak chitinase
inhibitors. Starting from the assumption that menthylated furanones could have structure
analogy with the most potent chitinase inhibitor allosamidin (75), the synthesis of
glycosylated furanones was attempted. The main purpose was to replace the menthyl group by
a monosaccharide or a disaccharide in a very short and very cheap process.
The starting furanone 37 was treated with trichloroacetonitrile to give the
trichloroacetimidate 93, which was submitted to glycosylation following a “reversed type
Schmidt glycosylation” procedure using TMSOTf as Lewis acid. The obtained acetylated
compounds 92, 96, and 97 were treated with guanidine. The deacetylated monosaccharides
101 and 102 were obtained in low yields whereas 97 was not completely deacetylated.
The glycosylation afforded for each compounds 92, 96, and 97 a mixture of four
diastereomers. Only the diastereomers of 96 could be partially separated by chromatography
on silica gel. The structures of the α-anomers could not be completely elucidated, whereas the
structures of the β-anomers could be obtained from an X-ray structure determination of 96d.
The starting furanone 37 was also treated with (+)-isomenthol and (+)-menthol to give
the compounds 104 and 105 respectively. These compounds, as well as the glycosylated
furanones 92, 96a, 96b, 96c, 96d, 102, 104, and 105, were tested but none of these synthetic
furanones were active as chitinase inhibitors.
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